

## SUMMARY OF PRODUCT CHARACTERISTICS

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

### 1 NAME OF THE MEDICINAL PRODUCT

Mounjaro 7.5 mg KwikPen solution for injection in pre-filled pen

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Pre-filled pen, multiple-dose KwikPen

*Mounjaro 7.5 mg KwikPen solution for injection in pre-filled pen*

Each multiple-dose pre-filled pen contains 4 doses of 0.6 ml solution which can be administered.

Each dose (0.6 ml) contains 7.5 mg of tirzepatide.

Excipients with known effect: Each multiple-dose pre-filled pen contains 5.4 mg Benzyl Alcohol [E1519] in each 0.6 ml dose.

For the full list of excipients, see section 6.1.

### 3 PHARMACEUTICAL FORM

Solution for injection.

Clear, colourless to slightly yellow solution.

### 4 CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

Mounjaro is indicated:

1. For the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
  - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  - in addition to other medicinal products for the treatment of diabetes.
2. For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of
  - $\geq 30 \text{ kg/ m}^2$  (obesity) or
  - $\geq 27 \text{ kg/ m}^2$  to  $< 30 \text{ kg/ m}^2$  (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

For study results with respect to combinations, effects on glycaemic control, weight reduction and the populations studied, see sections 4.4, 4.5 and 5.1.

For trial results with respect to obstructive sleep apnoea (OSA) and to heart failure with preserved ejection fraction (HFpEF), see section 5.1.

## **4 CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Mounjaro is indicated:

3. For the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
  - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  - in addition to other medicinal products for the treatment of diabetes.
4. For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of
  - $\geq 30 \text{ kg/ m}^2$  (obesity) or
  - $\geq 27 \text{ kg/ m}^2$  to  $< 30 \text{ kg/ m}^2$  (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

For study results with respect to combinations, effects on glycaemic control, weight reduction and the populations studied, see sections 4.4, 4.5 and 5.1.

For trial results with respect to obstructive sleep apnoea (OSA) and to heart failure with preserved ejection fraction (HFpEF), see section 5.1.

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

### **4.4 Special warnings and precautions for use**

#### Acute pancreatitis

Tirzepatide has not been studied in patients with a history of pancreatitis, and should be used with caution in these patients.

Acute pancreatitis has been reported in patients treated with tirzepatide. This includes post-marketing reports of necrotising pancreatitis and reports with a fatal outcome. Patients should be informed of the symptoms of acute pancreatitis, including persistent, severe abdominal pain. Patients should be advised to seek immediate medical attention if they occur. If pancreatitis is suspected, tirzepatide should be discontinued. If the diagnosis of pancreatitis is confirmed, tirzepatide should not be restarted.

In the absence of other signs and symptoms of acute pancreatitis, elevations in pancreatic enzymes alone are not predictive of acute pancreatitis (see section 4.8).

#### Hypoglycaemia in patients with type 2 diabetes mellitus

Patients receiving tirzepatide in combination with an insulin secretagogue (for example, a sulphonylurea) or insulin may have an increased risk of hypoglycaemia. The risk of hypoglycaemia may be lowered by a reduction in the dose of the insulin secretagogue or insulin (see sections 4.2 and 4.8).

#### Gastrointestinal effects

Tirzepatide has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhoea (see section 4.8). These adverse reactions may lead to dehydration, which could lead to a deterioration in renal function including acute renal failure. Patients treated with tirzepatide should be advised of the potential risk of dehydration, due to the gastrointestinal adverse reactions and take precautions to avoid fluid depletion and electrolyte disturbances. This should particularly be considered in the elderly, who may be more susceptible to such complications.

#### Severe gastrointestinal disease

Tirzepatide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and should be used with caution in these patients.

### Diabetic retinopathy

Tirzepatide has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy or diabetic macular oedema, and should be used with caution in these patients with appropriate monitoring.

### Elderly

Only very limited data are available from patients aged  $\geq 85$  years.

### Aspiration in association with general anaesthesia or deep sedation

Cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists undergoing general anaesthesia or deep sedation. Therefore, the increased risk of residual gastric content due to delayed gastric emptying (see section 4.8) should be considered prior to performing procedures with general anaesthesia or deep sedation.

### Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

### Benzyl Alcohol [E1519]

This medicine contains 5.4 mg Benzyl Alcohol [E1519] in each 0.6 ml dose.

Benzyl alcohol may cause allergic reactions.

Patients with hepatic or renal impairment should be informed of the potential risk of metabolic acidosis due to accumulation of benzyl alcohol over time.

## **4.5 Interaction with other medicinal products and other forms of interaction**

Tirzepatide delays gastric emptying and thereby has the potential to impact the rate of absorption of concomitantly administered oral medicinal products. This effect, resulting in decreased  $C_{\max}$  and a delayed  $t_{\max}$ , is most pronounced at the time of tirzepatide treatment initiation.

Based on the results from a study with paracetamol, which was used as a model medicinal product to evaluate the effect of tirzepatide on gastric emptying, no dose adjustments are expected to be required for most concomitantly administered oral medicinal products. However, it is recommended to monitor patients on oral medicinal products with a narrow therapeutic index (e.g., warfarin, digoxin), especially at initiation of - tirzepatide treatment and following dose increase. The risk of delayed effect should also be considered for oral medicinal products for which a rapid onset of effect is of importance.

### Paracetamol

No dose adjustment of paracetamol is necessary when administered with tirzepatide. Following a 5 mg single dose of tirzepatide, the maximum plasma

concentration ( $C_{\max}$ ) of paracetamol was reduced by 50 %, and the median ( $t_{\max}$ ) was delayed by 1 hour. The effect of tirzepatide on the oral absorption of paracetamol is dose and time dependent. At low doses (0.5 and 1.5 mg), there was only a minor change in paracetamol exposure. After four consecutive weekly doses of tirzepatide (5/5/8/10 mg), no effect on the paracetamol  $C_{\max}$  and  $t_{\max}$  was observed. The overall exposure (AUC) was not influenced.

#### Oral contraceptives

Administration of a combination oral contraceptive (0.035 mg ethinyl estradiol plus 0.25 mg norgestimate, a prodrug of norelgestromin) in the presence of a single dose of tirzepatide (5 mg) resulted in a reduction of oral contraceptive  $C_{\max}$  and area under the curve (AUC). Ethinyl estradiol  $C_{\max}$  was reduced by 59 % and AUC by 20 % with a delay in  $t_{\max}$  of 4 hours. Norelgestromin  $C_{\max}$  was reduced by 55 % and AUC by 23 % with a delay in  $t_{\max}$  of 4.5 hours. Norgestimate  $C_{\max}$  was reduced by 66 %, and AUC by 20 % with a delay in  $t_{\max}$  of 2.5 hours. This reduction in exposure after a single dose of tirzepatide is not considered clinically relevant. No dose adjustment of oral contraceptives is required in women with normal BMI.

There is limited information about the effect of tirzepatide on the pharmacokinetics and efficacy of oral contraceptives in women with obesity or overweight. Since reduced efficacy of oral contraceptives cannot be excluded, it is advised switching to a non-oral contraceptive method, or add a barrier method of contraception upon initiating tirzepatide therapy (for 4 weeks), or after each dose escalation (for 4 weeks).

## **4.6 Fertility, pregnancy and lactation**

### Pregnancy

There are no or a limited amount of data from the use of tirzepatide in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Tirzepatide should not be used during pregnancy and is not recommended in women of childbearing potential not using contraception. If a patient wishes to become pregnant, tirzepatide should be discontinued at least 1 month before a planned pregnancy due to the long half-life of tirzepatide.

### Breast-feeding

In a study of 11 women, the concentration of tirzepatide in breastmilk was found to be undetectable to very low (<10 ng/ml) compared to plasma concentrations following a single 5 mg dose. As tirzepatide is an amino acid sequence, any low amount present in breastmilk is expected to be degraded and not orally absorbed as intact drug by the breastfed infant. It is not known whether the reduced maternal food intake caused by tirzepatide affects composition or nutrient content of the breast milk. Overall, tirzepatide could be considered for use during breast-feeding.

### Fertility

The effect of tirzepatide on fertility in humans is unknown.

Animal studies with tirzepatide did not indicate direct harmful effects with respect to fertility (see section 5.3).

#### **4.7 Effects on ability to drive and use machines**

Tirzepatide has no or negligible influence on the ability to drive or use machines. When tirzepatide is used in combination with a sulphonylurea or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines (see section 4.4).

#### **4.8 Undesirable effects**

##### Summary of safety profile

In 13 completed phase 3 studies, 8 522 adult patients were exposed to tirzepatide alone or in combination with other glucose lowering medicinal products. The most frequently reported adverse reactions were gastrointestinal disorders. In general, these reactions were mostly mild or moderate in severity. The incidence of nausea, diarrhoea and vomiting occurred primarily during dose escalation and decreased over time (see sections 4.2, and 4.4).

##### Tabulated list of adverse reactions

The following related adverse reactions from clinical studies are listed below by system organ class and in order of decreasing incidence (very common:  $\geq 1/10$ ; common:  $\geq 1/100$  to  $< 1/10$ ; uncommon:  $\geq 1/1\ 000$  to  $< 1/100$ ; rare:  $\geq 1/10\ 000$  to  $< 1/1\ 000$ ; very rare:  $< 1/10\ 000$ ). Within each incidence grouping, adverse reactions are presented in order of decreasing frequency.

**Table 1. Adverse reactions**

<b>System organ class</b>	<b>Very common</b>	<b>Common</b>	<b>Uncommon</b>	<b>Rare</b>
<b>Immune system disorders</b>		Hypersensitivity reactions		Anaphylactic reaction <sup>#</sup> , Angioedema <sup>#</sup>
<b>Metabolism and nutrition disorders</b>	Hypoglycaemia <sup>1*</sup> when used with sulphonylurea or insulin	Hypoglycaemia <sup>1*</sup> when used with metformin and SGLT2i <sup>a</sup> , Decreased appetite <sup>1</sup>	Hypoglycaemia <sup>1*</sup> when used with metformin <sup>3</sup> , Weight decreased <sup>1</sup>	
<b>Nervous system disorders</b>		Dizziness <sup>2</sup>	Dysgeusia, Dysaesthesia	
<b>Vascular disorders</b>		Hypotension related events <sup>2**</sup>		
<b>Gastrointestinal disorders</b>	Nausea, Diarrhoea, Vomiting <sup>4</sup> , Constipation <sup>2</sup> , Abdominal pain <sup>4</sup>	Dyspepsia, Vomiting <sup>1</sup> , Constipation <sup>1</sup> , Abdominal pain <sup>1</sup> , Abdominal distention, Eructation, Flatulence, Gastroesophageal reflux disease, Cholelithiasis <sup>2</sup>	Cholelithiasis <sup>1</sup> , Cholecystitis <sup>2</sup> , Acute pancreatitis, Delayed gastric emptying	
<b>Skin and subcutaneous tissue disorders</b>		Hair loss <sup>2</sup>		
<b>General disorders and administration site conditions</b>		Fatigue <sup>†</sup> , Injection site reactions	Injection site pain	
<b>Investigations</b>		Heart rate increased <sup>1</sup> , Blood calcitonin increased <sup>2</sup> , Lipase increased, Amylase increased <sup>1</sup>	Blood calcitonin increased <sup>1</sup> , Heart rate increased <sup>2</sup> , Amylase increased <sup>2</sup>	

<sup>#</sup>From post-marketing reports.

<sup>\*</sup>Hypoglycaemia defined below.

<sup>†</sup>Fatigue includes the terms fatigue, asthenia, malaise, and lethargy.

<sup>\*\*</sup>“hypotension-related” events include “blood pressure decreased,” “hypotension,” and “orthostatic hypotension”. In Weight Management placebo-controlled trials, hypotension-related events were observed, 94% of the events observed were mild to moderate.

<sup>1</sup>Frequency reported in clinical trials supporting the type 2 diabetes indication.

<sup>2</sup>Frequency reported in clinical trials supporting the weight management indication.

<sup>3</sup>Frequency was common in the paediatric type 2 diabetes mellitus trial

<sup>4</sup>Frequency was very common in the weight management and in the paediatric type 2 diabetes mellitus trials.

<sup>a</sup> sodium-glucose co-transporter 2 inhibitor.

Tirzepatide was evaluated in a placebo-controlled phase 3 study (SUMMIT) in adults with HFpEF and obesity and in 2 placebo-controlled phase 3 studies (SURMOUNT-OSA) in

adults with OSA and obesity (see section 5.1). The adverse drug reactions were consistent with those reported in the pooled, placebo-controlled clinical trials for weight management.

The frequencies of adverse drug reactions in Table 1 reflect those observed in clinical trials in adults. Adverse drug reactions in the placebo-controlled period of the clinical trial with paediatric patients aged 10 to less than 18 years with type 2 diabetes mellitus were similar with the exception of the frequencies of hypoglycaemia with metformin alone (common), vomiting (very common), abdominal pain (very common) and blood calcitonin (very rare).

### Description of selected adverse reactions

#### Hypersensitivity reactions

Hypersensitivity reactions have been reported with tirzepatide in pooled adult type 2 diabetes mellitus placebo-controlled studies, pooled placebo-controlled weight management studies (SURMOUNT-1, -2, and -3), pooled placebo-controlled OSA studies and a placebo-controlled HFpEF phase 3 study, sometimes severe (e.g., urticaria, eczema, dermatitis and rash). Hypersensitivity reactions were reported in 3.2 %, 5.0 %, 3.0 %, and 4.7 % of tirzepatide-treated patients, respectively, compared to 1.7 %, 3.8 %, 2.1 %, and 3.5 % of placebo-treated patients, respectively.

Cases of anaphylactic reaction and angioedema have been rarely reported with tirzepatide during post-marketing surveillance.

#### Hypoglycaemia in patients with type 2 diabetes mellitus in adults

##### *SURPASS 1-to-5*

Clinically significant hypoglycaemia (blood glucose < 3.0 mmol/L (< 54 mg/dL)) or severe hypoglycaemia (requiring the assistance of another person) occurred in 10 to 14 % (0.14 to 0.16 events/patient year) of patients when tirzepatide was added to sulphonylurea and in 14 to 19 % (0.43 to 0.64 events/patient year) of patients when tirzepatide was added to basal insulin.

The rate of clinically significant hypoglycaemia when tirzepatide was used as monotherapy or when added to other oral antidiabetic medicinal products was up to 0.04 events/patient year (see table 1 and sections 4.2, 4.4 and 5.1).

In phase 3 clinical studies, 10 (0.2 %) patients reported 12 episodes of severe hypoglycaemia. Of these 10 patients, 5 (0.1 %) were on a background of insulin glargine or sulphonylurea who reported 1 episode each.

##### *SURMOUNT- 2*

Clinically significant hypoglycaemia (blood glucose < 3.0 mmol/L (< 54 mg/dL)) occurred in 4.2 % of tirzepatide-treated patients versus 1.3 % of placebo-treated patients.

The rate of clinically significant hypoglycaemic episodes was similar across tirzepatide 10 mg and 15 mg (4.3, and 6.1 events per 100 patient years of exposure, respectively) and the placebo-treated group (9.7 events per 100 patient years of exposure). The risk of hypoglycaemia was increased when tirzepatide was used with a sulphonylurea.

No cases of severe hypoglycaemia were reported.

## Gastrointestinal adverse reactions

### *Type 2 diabetes mellitus*

In pooled adult placebo-controlled type 2 diabetes mellitus phase 3 studies, gastrointestinal disorders were dose-dependently increased for tirzepatide 5 mg (37.1 %), 10 mg (39.6 %) and 15 mg (43.6 %) compared with placebo (20.4 %). Nausea occurred in 12.2 %, 15.4 % and 18.3 % versus 4.3 % and diarrhoea in 11.8 %, 13.3 % and 16.2 % versus 8.9 % for tirzepatide 5 mg, 10 mg, and 15 mg versus placebo. Gastrointestinal adverse reactions were mostly mild (74 %) or moderate (23.3 %) in severity. The incidence of nausea, vomiting, and diarrhoea was higher during the dose escalation period and decreased over time.

More patients treated with tirzepatide 5 mg (3.0 %), 10 mg (5.4 %) and 15 mg (6.6 %) discontinued permanently due to the gastrointestinal event compared with placebo (0.4%).

### *Weight management*

In pooled SURMOUNT-1 and SURMOUNT-2 phase 3 weight management studies, gastrointestinal disorders were 55.6 % for tirzepatide 5 mg, 55.8% for tirzepatide 10 mg and 55.6 % for tirzepatide 15 mg compared with placebo 29.7 %. Nausea occurred in 24.6 %, 29.0 % and 28.0 % versus 8.5 % and diarrhoea in 18.7 %, 20.8 % and 22.5 % versus 7.8 % for tirzepatide 5 mg, 10 mg and 15 mg versus placebo. Gastrointestinal adverse reactions were mostly mild (61.0 %) or moderate (34.4 %) in severity. The incidence of nausea, vomiting, and diarrhoea was higher during the dose escalation period and decreased over time.

More patients in the tirzepatide 5 mg (1.9 %), 10 mg (3.3 %) and 15 mg (4.3 %) groups compared to the placebo group (0.5 %) discontinued permanently due to the gastrointestinal event.

In pooled OSA phase 3 studies, gastrointestinal disorders were more common with tirzepatide (54.9 %) compared with placebo (23.5 %). Nausea occurred in 23.6 % versus 7.7 % and diarrhoea in 24.0 % versus 10.7 % for tirzepatide versus placebo. Gastrointestinal adverse reactions were mostly mild (59.4 %) or moderate (35.2 %) in severity. The incidence of nausea, vomiting, and diarrhoea was higher during the dose escalation period.

More patients in the tirzepatide group (2.1 %) compared to the placebo group (0.4 %) discontinued permanently due to the gastrointestinal event.

In a placebo controlled HFpEF phase 3 study, gastrointestinal disorders were more common with tirzepatide maximum tolerated dose (MTD, 54.1 %) compared with placebo (26.2 %). Diarrhoea occurred in 18.4 % versus 6.3 %, and nausea in 17.0 % versus 6.5 % for tirzepatide MTD versus placebo. Gastrointestinal adverse reactions were mostly mild (48.7 %) or moderate (42.6 %) in severity. The incidence of nausea, vomiting, and diarrhoea was higher during the dose escalation period and decreased over time.

More patients in the tirzepatide MTD group (4.1 %) compared to the placebo group (0 %) discontinued study treatment permanently due to the gastrointestinal event.

### Gallbladder related disorders

#### *Type 2 diabetes mellitus*

In pooled placebo-controlled type 2 diabetes mellitus phase 3 studies, cholelithiasis was reported in 0.3% of tirzepatide-treated patients and 0 placebo-treated patients.

#### *Weight management*

In pooled SURMOUNT-1, -2, and -3 phase 3 weight management studies, in pooled placebo-controlled OSA phase 3 studies, and in a placebo-controlled HFpEF phase 3 study, acute gallbladder disease was reported in 2.0 %, 0.9 %, and 4.4 % of tirzepatide-treated patients, respectively, and in 1.6 %, 0.9 % and 2.7 % of placebo-treated patients, respectively.

In pooled SURMOUNT-1, -2, and -3 phase 3 weight management studies, and in a phase 3 HFpEF study, cholecystitis (including cholecystitis and cholecystitis acute) was reported by 0.6% and 2.2% of tirzepatide-treated patients, respectively, and by 0.2% and 1.1% of placebo-treated patients, respectively.

In pooled SURMOUNT-1, -2, and -3 phase 3 weight management studies, in pooled placebo-controlled OSA phase 3 studies and in a placebo-controlled HFpEF phase 3 study, cholelithiasis was reported by 1.1%, 0.9 % and 2.5% of tirzepatide-treated patients respectively, and by 1.0%, 0.9 % and 1.1% of placebo treated patients respectively.

In the weight management studies, acute gallbladder events were positively correlated with weight reduction.

### Hair loss

#### *Weight management*

In pooled SURMOUNT-1, -2 and -3 phase 3 weight management studies, hair loss was reported in 4.9% of patients treated with tirzepatide and in 1.0 % of patients treated with placebo. The events were mainly of mild severity and most patients recovered while on continued treatment. No tirzepatide patients discontinued drug or study due to hair loss.

### Immunogenicity

There was no identified clinically significant effect of anti-tirzepatide antibodies on pharmacokinetics or effectiveness of tirzepatide.

In phase 3 clinical studies, a total of 9 094 tirzepatide-treated patients were assessed for anti-drug antibodies (ADA). Across these studies, 45.1 - 65.1% developed treatment-emergent (TE) ADA during the on-treatment period. In 29.8 - 51.3% of the assessed patients, TE ADA were persistent (that is TE ADA present for a period of 16-weeks or greater). Up to 3 % and 2.3 % had neutralising antibodies against tirzepatide activity on the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, respectively and up to 1.2 % and 0.4 % had neutralising antibodies against native GIP and native GLP-1, respectively.

## Heart rate

### *Type 2 diabetes mellitus*

In pooled placebo-controlled type 2 diabetes mellitus, phase 3 studies in adult patients, treatment with tirzepatide resulted in a maximum mean increase in heart rate of 3 to 5 beats per minute across doses. The maximum mean increase in heart rate in placebo-treated patients was 1 beat per minute.

The incidence of patients who had a change of baseline heart rate of > 20 bpm for 2 or more consecutive visits was 2.1 %, 3.8 % and 2.9 %, for tirzepatide 5 mg, 10 mg and 15 mg, respectively, compared with 2.1 % for placebo.

Small mean increases in PR interval were observed with tirzepatide when compared to placebo (mean increase of 1.4 to 3.2 msec and mean decrease of 1.4 msec respectively). No difference in arrhythmia and cardiac conduction disorder treatment emergent events were observed between tirzepatide 5 mg, 10 mg, 15 mg and placebo (3.8 %, 2.1 %, 3.7 % and 3 % respectively).

### *Weight management*

In pooled SURMOUNT-1, -2, and -3 phase 3 weight management studies, in pooled OSA phase 3 studies, and in a HFpEF phase 3 study, treatment with tirzepatide resulted in a mean increase in heart rate of 3, 2 and 3 beats per minute, respectively. There was a mean increase in heart rate of <1, <1 and 1 beat per minute, respectively, in placebo-treated patients.

## Injection site reactions

In pooled placebo-controlled type 2 diabetes mellitus phase 3 studies in adult patients, in pooled SURMOUNT-1, -2, and -3 phase 3 weight management studies, in pooled placebo-controlled OSA phase 3 studies, and in a placebo-controlled phase 3 HFpEF study, injection site reactions were increased for tirzepatide (3.2 %, 8.0 %, 8.2 %, and 6.0 %, respectively) compared with placebo (0.4 %, 1.8 %, 2.6 %, and 1.6 %, respectively).

Overall, in phase 3 studies, the most common signs and symptoms of injection site reactions were erythema and pruritus. The maximum severity of injection site reactions for patients was mild (91 %) or moderate (9 %). No injection site reactions were serious.

## Pancreatic enzymes

The clinical significance of elevations in amylase or lipase with tirzepatide is unknown in the absence of other signs and symptoms of pancreatitis.

### *Type 2 diabetes mellitus*

In pooled placebo-controlled type 2 diabetes mellitus phase 3 studies, treatment in adult patients with tirzepatide resulted in mean increases from baseline in pancreatic amylase of 33 % to 38 % and lipase of 31 % to 42 % across doses. Placebo treated patients had an increase from baseline in amylase of 4 % and no changes were observed in lipase.

### *Weight management*

In pooled SURMOUNT-1, -2 and -3 phase 3 weight management studies, in pooled placebo-controlled OSA phase 3 studies, and in a placebo-controlled HFpEF phase 3 study, treatment with tirzepatide resulted in mean increases from baseline in serum pancreatic amylase concentrations of 23 %, 25 %, and 28 %, respectively, and lipase of 34 %, 39 %, and 32 %, respectively. Placebo treated patients had an increase from baseline in amylase of 2 %, 1 %, and 4 %, respectively, and in lipase of 6 %, 4 %, and 1 %, respectively.

### Paediatric Population

The safety and immunogenicity profiles in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus treated with tirzepatide 5 mg and 10 mg once-weekly were consistent with those described above for adult patients with type 2 diabetes mellitus with the exception of a higher frequency of vomiting, abdominal pain, and hypoglycemia when added to metformin alone.

No severe hypoglycaemic episodes occurred during the paediatric type 2 diabetes mellitus trial. During the placebo-controlled phase, clinically significant hypoglycaemia (blood glucose < 3.0 mmol/L (< 54 mg/dL)) occurred in 28.6 % (1.98 events/patient year) of patients treated with tirzepatide and in 10.0 % (0.35 events/patient year) of patients treated with placebo, when added to basal insulin with or without metformin. The rate was 9.1 % (0.28 events/patient year) and 4.2 % (0.07 events/patient year) for tirzepatide and placebo-treated patients, respectively, when added to metformin alone.

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

## **4.9 Overdose**

In the event of overdose, appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms. Patients may experience gastrointestinal adverse reactions including nausea. There is no specific antidote for overdose of tirzepatide. A prolonged period of observation and treatment of these symptoms may be necessary, taking into account the half-life of tirzepatide (approximately 5 days).

# **5 PHARMACOLOGICAL PROPERTIES**

## **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins, ATC code: A10BX16.

### Mechanism of action

Tirzepatide is a long acting GIP and GLP-1 receptor agonist. Both receptors are present on the pancreatic  $\alpha$  and  $\beta$  endocrine cells, heart, vasculature, immune cells (leukocytes), gut and kidney. GIP receptors are also present on adipocytes. Tirzepatide is highly selective to human GIP and GLP-1 receptors. Tirzepatide has high affinity to both the GIP and GLP-1 receptors. The activity of tirzepatide on the GIP receptor is similar to native GIP hormone. The activity of tirzepatide on the GLP-1 receptor is lower compared to native GLP-1 hormone.

In addition, both GIP and GLP-1 receptors are expressed in the areas of the brain important to appetite regulation. Animal studies show that tirzepatide distributes to and activates neurons in brain regions involved in regulation of appetite and food intake. Animal studies show that tirzepatide can modulate fat utilization through the GIP receptor. In human adipocytes cultured in vitro, tirzepatide acts on GIP receptors to regulate glucose uptake and modulate lipid uptake and lipolysis.

### Appetite regulation and energy metabolism

Tirzepatide lowers body weight and body fat mass. The mechanisms associated with body weight and body fat mass reduction involve decreased food intake through the regulation of appetite and modulation of fat utilization. Clinical studies show that tirzepatide reduces energy intake and appetite by increasing feelings of satiety (fullness), decreasing feelings of hunger, and decreasing food cravings.

Tirzepatide significantly decreased the amount of food consumed and calorie intake during ad libitum lunch, dinner and combined compared to placebo in people with obesity. Tirzepatide significantly lowered overall appetite as measured by retrospective visual analogue scale (VAS) throughout an 18-week period compared to placebo. Tirzepatide decreased hunger and prospective food consumption starting at week 1 of the treatment and increased satiety starting at week 3. Tirzepatide significantly decreased craving for fast-food fats, and sweets, carbohydrates and starches, except craving for vegetables and fruit, compared to placebo in people with obesity.

### Glycaemic control

Tirzepatide improves glycaemic control by lowering fasting and postprandial glucose concentrations in patients with type 2 diabetes through several mechanisms.

### Pharmacodynamic effects

#### Insulin secretion

Tirzepatide increases pancreatic  $\beta$ -cell glucose sensitivity. It enhances first- and second-phase insulin secretion in a glucose dependent manner.

In a hyperglycaemic clamp study in adult patients with type 2 diabetes, tirzepatide was compared to placebo and the selective GLP-1 receptor agonist semaglutide 1 mg for insulin secretion. Tirzepatide 15 mg enhanced the first and second-phase insulin secretion rate by 466 % and 302 % from baseline, respectively. There was no change in first- and second-phase insulin secretion rate for placebo.

### Insulin sensitivity

Tirzepatide improves insulin sensitivity.

In adults, tirzepatide 15 mg improved whole body insulin sensitivity by 63 %, as measured by M-value, a measure of glucose tissue uptake using hyperinsulinemic euglycaemic clamp. The M-value was unchanged for placebo.

Tirzepatide lowers body weight in patients with type 2 diabetes and in patients who are overweight or have obesity, which may contribute to improvement in insulin sensitivity. Reduced food intake with tirzepatide contributes to body weight loss. The body weight reduction is mostly due to reduced fat mass.

### Glucagon concentration

Tirzepatide reduced the fasting and postprandial glucagon concentrations in a glucose dependent manner. In adults, tirzepatide 15 mg reduced fasting glucagon concentration by 28 % and glucagon AUC after a mixed meal by 43 %, compared with no change for placebo.

### Gastric emptying

Tirzepatide delays gastric emptying which may slow post meal glucose absorption and can lead to a beneficial effect on postprandial glycaemia. Tirzepatide induced delay in gastric emptying diminishes over time.

### Clinical efficacy and safety

#### Type 2 diabetes mellitus in adults

The safety and efficacy of tirzepatide were evaluated in five global randomised, controlled, phase 3 studies (SURPASS 1-5) assessing glycaemic control as the primary objective. The studies involved 6 263 treated patients with type 2 diabetes (4 199 treated with tirzepatide). The secondary objectives included body weight, fasting serum glucose (FSG) and proportion of patients reaching target HbA1c. All five phase 3 studies assessed tirzepatide 5 mg, 10 mg and 15 mg. All patients treated with tirzepatide started with 2.5 mg for 4 weeks. Then the dose of tirzepatide was increased by 2.5 mg every 4 weeks until they reached their assigned dose.

Across all studies, treatment with tirzepatide demonstrated sustained, statistically significant and clinically meaningful reductions from baseline in HbA1c as the primary objective compared to either placebo or active control treatment (semaglutide, insulin degludec and insulin glargine) for up to 1 year. In 1 study these effects were sustained for up to 2 years. Statistically significant and clinically meaningful reductions from baseline in body weight were also demonstrated. Results from the phase 3 studies are presented below based on the on-treatment data without rescue therapy in the modified intent-to-treat (mITT) population consisting of all randomly assigned patients who were exposed to at least 1 dose of study treatment, excluding patients discontinuing study treatment due to inadvertent enrolment.

#### SURPASS 1 – Monotherapy

In a 40 week double blind placebo-controlled study, 478 patients with inadequate glycaemic control with diet and exercise, were randomised to tirzepatide 5 mg, 10 mg or 15 mg once weekly or placebo. Patients had a mean age of 54 years and 52 % were men. At baseline the patients had a mean duration of diabetes of 5 years and the mean BMI was 32 kg/m<sup>2</sup>.


**Table 2. SURPASS 1: Results at week 40**

		<b>Tirzepatide 5 mg</b>	<b>Tirzepatide 10 mg</b>	<b>Tirzepatide 15 mg</b>	<b>Placebo</b>
<b>mITT population (n)</b>		121	121	120	113
<b>HbA<sub>1c</sub> (%)</b>	Baseline (mean)	7.97	7.88	7.88	8.08
	Change from baseline	-1.87 <sup>##</sup>	-1.89 <sup>##</sup>	-2.07 <sup>##</sup>	+0.04
	Difference from placebo [95 % CI]	-1.91 <sup>**</sup> [-2.18, -1.63]	-1.93 <sup>**</sup> [-2.21, -1.65]	-2.11 <sup>**</sup> [-2.39, -1.83]	-
<b>HbA<sub>1c</sub> (mmol/mol)</b>	Baseline (mean)	63.6	62.6	62.6	64.8
	Change from baseline	-20.4 <sup>##</sup>	-20.7 <sup>##</sup>	-22.7 <sup>##</sup>	+0.4
	Difference from placebo [95 % CI]	-20.8 <sup>**</sup> [-23.9, -17.8]	-21.1 <sup>**</sup> [-24.1, -18.0]	-23.1 <sup>**</sup> [-26.2, -20.0]	-
<b>Patients (%) achieving HbA<sub>1c</sub></b>	< 7 %	86.8 <sup>**</sup>	91.5 <sup>**</sup>	87.9 <sup>**</sup>	19.6
	≤ 6.5 %	81.8 <sup>††</sup>	81.4 <sup>††</sup>	86.2 <sup>††</sup>	9.8
	< 5.7 %	33.9 <sup>**</sup>	30.5 <sup>**</sup>	51.7 <sup>**</sup>	0.9
<b>FSG (mmol/L)</b>	Baseline (mean)	8.5	8.5	8.6	8.6
	Change from baseline	-2.4 <sup>##</sup>	-2.6 <sup>##</sup>	-2.7 <sup>##</sup>	+0.7 <sup>#</sup>
	Difference from placebo [95 % CI]	-3.13 <sup>**</sup> [-3.71, -2.56]	-3.26 <sup>**</sup> [-3.84, -2.69]	-3.45 <sup>**</sup> [-4.04, -2.86]	-
<b>FSG (mg/dL)</b>	Baseline (mean)	153.7	152.6	154.6	155.2
	Change from baseline	-43.6 <sup>##</sup>	-45.9 <sup>##</sup>	-49.3 <sup>##</sup>	+12.9 <sup>#</sup>
	Difference from placebo [95 % CI]	-56.5 <sup>**</sup> [-66.8, -46.1]	-58.8 <sup>**</sup> [-69.2, -48.4]	-62.1 <sup>**</sup> [-72.7, -51.5]	-
<b>Body weight (kg)</b>	Baseline (mean)	87.0	85.7	85.9	84.4
	Change from baseline	-7.0 <sup>##</sup>	-7.8 <sup>##</sup>	-9.5 <sup>##</sup>	-0.7
	Difference from placebo [95 % CI]	-6.3 <sup>**</sup> [-7.8, -4.7]	-7.1 <sup>**</sup> [-8.6, -5.5]	-8.8 <sup>**</sup> [-10.3, -7.2]	-
<b>Patients (%) achieving weight loss</b>	≥ 5 %	66.9 <sup>††</sup>	78.0 <sup>††</sup>	76.7 <sup>††</sup>	14.3
	≥ 10 %	30.6 <sup>††</sup>	39.8 <sup>††</sup>	47.4 <sup>††</sup>	0.9
	≥ 15 %	13.2 <sup>†</sup>	17.0 <sup>†</sup>	26.7 <sup>†</sup>	0.0

\*p < 0.05, \*\* p < 0.001 for superiority, adjusted for multiplicity.

† p < 0.05, †† p < 0.001 compared to placebo, not adjusted for multiplicity.

# p < 0.05, ## p < 0.001 compared to baseline, not adjusted for multiplicity.



**Figure 1. Mean HbA<sub>1c</sub> (%) and mean body weight (kg) from baseline to week 40**

*SURPASS 2 - Combination therapy with metformin*

In a 40 week active-controlled open-label study, (double-blind with respect to tirzepatide dose assignment) 1 879 patients were randomised to tirzepatide 5 mg, 10 mg or 15 mg once weekly or semaglutide 1 mg once weekly, all in combination with metformin. Patients had a mean age of 57 years and 47 % were men. At baseline the patients had a mean duration of diabetes of 9 years and the mean BMI was 34 kg/m<sup>2</sup>.


**Table 3. SURPASS 2: Results at week 40**

		<b>Tirzepatide 5 mg</b>	<b>Tirzepatide 10 mg</b>	<b>Tirzepatide 15 mg</b>	<b>Semaglutide 1 mg</b>
<b>mITT population (n)</b>		470	469	469	468
<b>HbA<sub>1c</sub> (%)</b>	Baseline (mean)	8.33	8.31	8.25	8.24
	Change from baseline	-2.09 <sup>##</sup>	-2.37 <sup>##</sup>	-2.46 <sup>##</sup>	-1.86 <sup>##</sup>
	Difference from semaglutide [95 % CI]	-0.23 <sup>**</sup> [-0.36, -0.10]	-0.51 <sup>**</sup> [-0.64, -0.38]	-0.60 <sup>**</sup> [-0.73, -0.47]	-
<b>HbA<sub>1c</sub> (mmol/mol)</b>	Baseline (mean)	67.5	67.3	66.7	66.6
	Change from baseline	-22.8 <sup>##</sup>	-25.9 <sup>##</sup>	-26.9 <sup>##</sup>	-20.3 <sup>##</sup>
	Difference from semaglutide [95 % CI]	-2.5 <sup>**</sup> [-3.9, -1.1]	-5.6 <sup>**</sup> [-7.0, -4.1]	-6.6 <sup>**</sup> [-8.0, -5.1]	N/A
<b>Patients (%) achieving HbA<sub>1c</sub></b>	< 7 %	85.5 <sup>*</sup>	88.9 <sup>**</sup>	92.2 <sup>**</sup>	81.1
	≤ 6.5 %	74.0 <sup>†</sup>	82.1 <sup>††</sup>	87.1 <sup>††</sup>	66.2
	< 5.7 %	29.3 <sup>††</sup>	44.7 <sup>**</sup>	50.9 <sup>**</sup>	19.7
<b>FSG (mmol/L)</b>	Baseline (mean)	9.67	9.69	9.56	9.49
	Change from baseline	-3.11 <sup>##</sup>	-3.42 <sup>##</sup>	-3.52 <sup>##</sup>	-2.70 <sup>##</sup>
	Difference from semaglutide [95 % CI]	-0.41 <sup>†</sup> [-0.65, -0.16]	-0.72 <sup>††</sup> [-0.97, -0.48]	-0.82 <sup>††</sup> [-1.06, -0.57]	-
<b>FSG (mg/dL)</b>	Baseline (mean)	174.2	174.6	172.3	170.9
	Change from baseline	-56.0 <sup>##</sup>	-61.6 <sup>##</sup>	-63.4 <sup>##</sup>	-48.6 <sup>##</sup>
	Difference from semaglutide [95 % CI]	-7.3 <sup>†</sup> [-11.7, -3.0]	-13.0 <sup>††</sup> [-17.4, -8.6]	-14.7 <sup>††</sup> [-19.1, -10.3]	-
<b>Body weight (kg)</b>	Baseline (mean)	92.6	94.9	93.9	93.8
	Change from baseline	-7.8 <sup>##</sup>	-10.3 <sup>##</sup>	-12.4 <sup>##</sup>	-6.2 <sup>##</sup>
	Difference from semaglutide [95 % CI]	-1.7 <sup>**</sup> [-2.6, -0.7]	-4.1 <sup>**</sup> [-5.0, -3.2]	-6.2 <sup>**</sup> [-7.1, -5.3]	-
<b>Patients (%) achieving weight loss</b>	≥ 5 %	68.6 <sup>†</sup>	82.4 <sup>††</sup>	86.2 <sup>††</sup>	58.4
	≥ 10 %	35.8 <sup>††</sup>	52.9 <sup>††</sup>	64.9 <sup>††</sup>	25.3
	≥ 15 %	15.2 <sup>†</sup>	27.7 <sup>††</sup>	39.9 <sup>††</sup>	8.7

\*p < 0.05, \*\* p < 0.001 for superiority, adjusted for multiplicity.

† p < 0.05, †† p < 0.001 compared to semaglutide 1 mg, not adjusted for multiplicity.

# p < 0.05, ## p < 0.001 compared to baseline, not adjusted for multiplicity.



**Figure 2. Mean HbA<sub>1c</sub> (%) and mean body weight (kg) from baseline to week 40**

*SURPASS 3 - Combination therapy with metformin, with or without SGLT2i*

In a 52 week active-controlled open-label study, 1 444 patients were randomised to tirzepatide 5 mg, 10 mg or 15 mg once weekly or insulin degludec, all in combination with metformin with or without a SGLT2i. 32 % of patients were using SGLT2i at baseline. At baseline the patients had a mean duration of diabetes of 8 years, a mean BMI of 34 kg/m<sup>2</sup>, a mean age of 57 years and 56 % were men.

Patients treated with insulin degludec started at a dose of 10 U/day which was adjusted using an algorithm for a target fasting blood glucose of < 5 mmol/L. The mean dose of insulin degludec at week 52 was 49 units/day.


**Table 4. SURPASS 3: Results at week 52**

		<b>Tirzepatide 5 mg</b>	<b>Tirzepatide 10 mg</b>	<b>Tirzepatide 15 mg</b>	<b>Titrated insulin degludec</b>
<b>mITT population (n)</b>		358	360	358	359
<b>HbA<sub>1c</sub> (%)</b>	Baseline (mean)	8.17	8.19	8.21	8.13
	Change from baseline	-1.93 <sup>##</sup>	-2.20 <sup>##</sup>	-2.37 <sup>##</sup>	-1.34 <sup>##</sup>
	Difference from insulin degludec [95 % CI]	-0.59 <sup>**</sup> [-0.73, -0.45]	-0.86 <sup>**</sup> [-1.00, -0.72]	-1.04 <sup>**</sup> [-1.17, -0.90]	-
<b>HbA<sub>1c</sub> (mmol/mol)</b>	Baseline (mean)	65.8	66.0	66.3	65.4
	Change from baseline	-21.1 <sup>##</sup>	-24.0 <sup>##</sup>	-26.0 <sup>##</sup>	-14.6 <sup>##</sup>
	Difference from insulin degludec [95 % CI]	-6.4 <sup>**</sup> [-7.9, -4.9]	-9.4 <sup>**</sup> [-10.9, -7.9]	-11.3 <sup>**</sup> [-12.8, -9.8]	-
<b>Patients (%) achieving HbA<sub>1c</sub></b>	< 7 %	82.4 <sup>**</sup>	89.7 <sup>**</sup>	92.6 <sup>**</sup>	61.3
	≤ 6.5 %	71.4 <sup>††</sup>	80.3 <sup>††</sup>	85.3 <sup>††</sup>	44.4
	< 5.7 %	25.8 <sup>††</sup>	38.6 <sup>††</sup>	48.4 <sup>††</sup>	5.4
<b>FSG (mmol/L)</b>	Baseline (mean)	9.54	9.48	9.35	9.24
	Change from baseline	-2.68 <sup>##</sup>	-3.04 <sup>##</sup>	-3.29 <sup>##</sup>	-3.09 <sup>##</sup>
	Difference from insulin degludec [95 % CI]	0.41 <sup>†</sup> [0.14, 0.69]	0.05 [-0.24, 0.33]	-0.20 [-0.48, 0.08]	-
<b>FSG (mg/dL)</b>	Baseline (mean)	171.8	170.7	168.4	166.4
	Change from baseline	-48.2 <sup>##</sup>	-54.8 <sup>##</sup>	-59.2 <sup>##</sup>	-55.7 <sup>##</sup>
	Difference from insulin degludec [95 % CI]	7.5 <sup>†</sup> [2.4, 12.5]	0.8 [-4.3, 5.9]	-3.6 [-8.7, 1.5]	-
<b>Body weight (kg)</b>	Baseline (mean)	94.5	94.3	94.9	94.2
	Change from baseline	-7.5 <sup>##</sup>	-10.7 <sup>##</sup>	-12.9 <sup>##</sup>	+2.3 <sup>##</sup>
	Difference from insulin degludec [95 % CI]	-9.8 <sup>**</sup> [-10.8, -8.8]	-13.0 <sup>**</sup> [-14.0, -11.9]	-15.2 <sup>**</sup> [-16.2, -14.2]	-
<b>Patients (%) achieving weight loss</b>	≥ 5 %	66.0 <sup>††</sup>	83.7 <sup>††</sup>	87.8 <sup>††</sup>	6.3
	≥ 10 %	37.4 <sup>††</sup>	55.7 <sup>††</sup>	69.4 <sup>††</sup>	2.9
	≥ 15 %	12.5 <sup>††</sup>	28.3 <sup>††</sup>	42.5 <sup>††</sup>	0.0

\*p < 0.05, \*\*p < 0.001 for superiority, adjusted for multiplicity.

† p < 0.05, †† p < 0.001 compared to insulin degludec, not adjusted for multiplicity.

# p < 0.05, ## p < 0.001 compared to baseline, not adjusted for multiplicity.



**Figure 3. Mean HbA<sub>1c</sub> (%) and mean body weight (kg) from baseline to week 52**

## Continuous glucose monitoring (CGM)

A subset of patients (N = 243) participated in an evaluation of the 24 hour glucose profiles captured with blinded CGM. At 52 weeks, patients treated with tirzepatide (10 mg and 15 mg pooled) spent significantly more time with glucose values in the euglycaemic range defined as 71 to 140 mg/dL (3.9 to 7.8 mmol/L) compared to patients treated with insulin degludec, with 73 % and 48 % of the 24 hour period in range, respectively.

### *SURPASS 4 – Combination therapy with 1-3 oral antidiabetic medicinal products: metformin, sulphonylureas or SGLT2i*

In an active-controlled open-label study of up to 104 weeks (primary endpoint at 52 weeks), 2 002 patients with type 2 diabetes and increased cardiovascular risk were randomised to tirzepatide 5 mg, 10 mg or 15 mg once weekly or insulin glargine once daily on a background of metformin (95 %) and/or sulphonylureas (54 %) and/or SGLT2i (25 %). At baseline the patients had a mean duration of diabetes of 12 years, a mean BMI of 33 kg/m<sup>2</sup>, a mean age of 64 years and 63 % were men. Patient treated with insulin glargine started at a dose of 10 U/day which was adjusted using an algorithm with a fasting blood glucose target of < 5.6 mmol/L. The mean dose of insulin glargine at week 52 was 44 units/day.


**Table 5. SURPASS 4: Results at week 52**

		<b>Tirzepatide 5 mg</b>	<b>Tirzepatide 10 mg</b>	<b>Tirzepatide 15 mg</b>	<b>Titrated insulin glargine</b>
<b>mITT population (n)</b>		328	326	337	998
<b>52 weeks</b>					
<b>HbA<sub>1c</sub> (%)</b>	Baseline (mean)	8.52	8.60	8.52	8.51
	Change from baseline	-2.24 <sup>##</sup>	-2.43 <sup>##</sup>	-2.58 <sup>##</sup>	-1.44 <sup>##</sup>
	Difference from insulin glargine [95 % CI]	-0.80 <sup>**</sup> [-0.92, -0.68]	-0.99 <sup>**</sup> [-1.11, -0.87]	-1.14 <sup>**</sup> [-1.26, -1.02]	-
<b>HbA<sub>1c</sub> (mmol/mol)</b>	Baseline (mean)	69.6	70.5	69.6	69.5
	Change from baseline	-24.5 <sup>##</sup>	-26.6 <sup>##</sup>	-28.2 <sup>##</sup>	-15.7 <sup>##</sup>
	Difference from insulin glargine [95 % CI]	-8.8 <sup>**</sup> [-10.1, -7.4]	-10.9 <sup>**</sup> [-12.3, -9.6]	-12.5 <sup>**</sup> [-13.8, -11.2]	-
<b>Patients (%) achieving HbA<sub>1c</sub></b>	< 7 %	81.0 <sup>**</sup>	88.2 <sup>**</sup>	90.7 <sup>**</sup>	50.7
	≤ 6.5 %	66.0 <sup>††</sup>	76.0 <sup>††</sup>	81.1 <sup>††</sup>	31.7
	< 5.7 %	23.0 <sup>††</sup>	32.7 <sup>††</sup>	43.1 <sup>††</sup>	3.4
<b>FSG (mmol/L)</b>	Baseline (mean)	9.57	9.75	9.67	9.37
	Change from baseline	-2.80 <sup>##</sup>	-3.06 <sup>##</sup>	-3.29 <sup>##</sup>	-2.84 <sup>##</sup>
	Difference from insulin glargine [95 % CI]	0.04 [-0.22, 0.30]	-0.21 [-0.48, 0.05]	-0.44 <sup>††</sup> [-0.71, -0.18]	-
<b>FSG (mg/dL)</b>	Baseline (mean)	172.3	175.7	174.2	168.7
	Change from baseline	-50.4 <sup>##</sup>	-54.9 <sup>##</sup>	-59.3 <sup>##</sup>	-51.4 <sup>##</sup>
	Difference from insulin glargine [95 % CI]	1.0 [-3.7, 5.7]	-3.6 [-8.2, 1.1]	-8.0 <sup>††</sup> [-12.6, -3.4]	-
<b>Body weight (kg)</b>	Baseline (mean)	90.3	90.7	90.0	90.3
	Change from baseline	-7.1 <sup>##</sup>	-9.5 <sup>##</sup>	-11.7 <sup>##</sup>	+1.9 <sup>##</sup>
	Difference from insulin glargine [95 % CI]	-9.0 <sup>**</sup> [-9.8, -8.3]	-11.4 <sup>**</sup> [-12.1, -10.6]	-13.5 <sup>**</sup> [-14.3, -12.8]	-
<b>Patients (%) achieving weight loss</b>	≥ 5 %	62.9 <sup>††</sup>	77.6 <sup>††</sup>	85.3 <sup>††</sup>	8.0
	≥ 10 %	35.9 <sup>††</sup>	53.0 <sup>††</sup>	65.6 <sup>††</sup>	1.5
	≥ 15 %	13.8 <sup>††</sup>	24.0 <sup>††</sup>	36.5 <sup>††</sup>	0.5

\* p < 0.05, \*\* p < 0.001 for superiority, adjusted for multiplicity.

† p < 0.05, †† p < 0.001 compared to insulin glargine, not adjusted for multiplicity.

# p < 0.05, ## p < 0.001 compared to baseline, not adjusted for multiplicity.



**Figure 4. Mean HbA<sub>1c</sub> (%) and mean body weight (kg) from baseline to week 52**

*SURPASS 5 - Combination therapy with titrated basal insulin, with or without metformin*

In a 40 week double-blind placebo-controlled study, 475 patients with inadequate glycaemic control using insulin glargine with or without metformin were randomised to tirzepatide 5 mg, 10 mg or 15 mg once weekly or placebo. Insulin glargine doses were adjusted utilizing an algorithm with a fasting blood glucose target of < 5.6 mmol/L. At baseline the patients had a mean duration of diabetes of 13 years, a mean BMI of 33 kg/m<sup>2</sup>, a mean age of 61 years and 56 % were men. The overall estimated median dose of insulin glargine at baseline was 34 units/day. The median dose of insulin glargine at week 40 was 38, 36, 29 and 59 units/day for tirzepatide 5 mg, 10 mg, 15 mg and placebo respectively.


**Table 6. SURPASS 5: Results at week 40**

		<b>Tirzepatide 5 mg</b>	<b>Tirzepatide 10 mg</b>	<b>Tirzepatide 15 mg</b>	<b>Placebo</b>
<b>mITT population (n)</b>		116	118	118	119
<b>HbA<sub>1c</sub> (%)</b>	Baseline (mean)	8.29	8.34	8.22	8.39
	Change from baseline	-2.23 <sup>##</sup>	-2.59 <sup>##</sup>	-2.59 <sup>##</sup>	-0.93 <sup>##</sup>
	Difference from placebo [95 % CI]	-1.30 <sup>**</sup> [-1.52, -1.07]	-1.66 <sup>**</sup> [-1.88, -1.43]	-1.65 <sup>**</sup> [-1.88, -1.43]	-
<b>HbA<sub>1c</sub> (mmol/mol)</b>	Baseline (mean)	67.1	67.7	66.4	68.2
	Change from baseline	-24.4 <sup>##</sup>	-28.3 <sup>##</sup>	-28.3 <sup>##</sup>	-10.2 <sup>##</sup>
	Difference from placebo [95 % CI]	-14.2 <sup>**</sup> [-16.6, -11.7]	-18.1 <sup>**</sup> [-20.6, -15.7]	-18.1 <sup>**</sup> [-20.5, -15.6]	-
<b>Patients (%) achieving HbA<sub>1c</sub></b>	< 7 %	93.0 <sup>**</sup>	97.4 <sup>**</sup>	94.0 <sup>**</sup>	33.9
	≤ 6.5 %	80.0 <sup>††</sup>	94.7 <sup>††</sup>	92.3 <sup>††</sup>	17.0
	< 5.7 %	26.1 <sup>††</sup>	47.8 <sup>††</sup>	62.4 <sup>††</sup>	2.5
<b>FSG (mmol/L)</b>	Baseline (mean)	9.00	9.04	8.91	9.13
	Change from baseline	-3.41 <sup>##</sup>	-3.77 <sup>##</sup>	-3.76 <sup>##</sup>	-2.16 <sup>##</sup>
	Difference from placebo [95 % CI]	-1.25 <sup>**</sup> [-1.64, -0.86]	-1.61 <sup>**</sup> [-2.00, -1.22]	-1.60 <sup>**</sup> [-1.99, -1.20]	-
<b>FSG (mg/dL)</b>	Baseline (mean)	162.2	162.9	160.4	164.4
	Change from baseline	-61.4 <sup>##</sup>	-67.9 <sup>##</sup>	-67.7 <sup>##</sup>	-38.9 <sup>##</sup>
	Difference from placebo [95 % CI]	-22.5 <sup>**</sup> [-29.5, -15.4]	-29.0 <sup>**</sup> [-36.0, -22.0]	-28.8 <sup>**</sup> [-35.9, -21.6]	-
<b>Body weight (kg)</b>	Baseline (mean)	95.5	95.4	96.2	94.1
	Change from baseline	-6.2 <sup>##</sup>	-8.2 <sup>##</sup>	-10.9 <sup>##</sup>	+1.7 <sup>#</sup>
	Difference from placebo [95 % CI]	-7.8 <sup>**</sup> [-9.4, -6.3]	-9.9 <sup>**</sup> [-11.5, -8.3]	-12.6 <sup>**</sup> [-14.2, -11.0]	-
<b>Patients (%) achieving weight loss</b>	≥ 5 %	53.9 <sup>††</sup>	64.6 <sup>††</sup>	84.6 <sup>††</sup>	5.9
	≥ 10 %	22.6 <sup>††</sup>	46.9 <sup>††</sup>	51.3 <sup>††</sup>	0.9
	≥ 15 %	7.0 <sup>†</sup>	26.6 <sup>†</sup>	31.6 <sup>††</sup>	0.0

\*p < 0.05, \*\* p < 0.001 for superiority, adjusted for multiplicity.

† p < 0.05, †† p < 0.001 compared to placebo, not adjusted for multiplicity.

# p < 0.05, ## p < 0.001 compared to baseline, not adjusted for multiplicity.



**Figure 5. Mean HbA<sub>1c</sub> (%) and mean body weight (kg) from baseline to week 40**

### Cardiovascular evaluation

Cardiovascular (CV) risk was assessed via a meta-analysis of patients with at least one adjudication confirmed major adverse cardiac event (MACE). The composite endpoint of MACE-4 included CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalisation for unstable angina.

In a primary meta-analysis of phase 2 and 3 registration studies in patients with type 2 diabetes, a total of 116 patients (tirzepatide: 60 [n = 4 410]; all comparators: 56 [n = 2 169]) experienced at least one adjudication confirmed MACE-4: The results showed that tirzepatide was not associated with excess risk for CV events compared with pooled comparators (HR: 0.81; CI: 0.52 to 1.26).

An additional analysis was conducted specifically for the SURPASS-4 study that enrolled patients with established CV disease. A total of 109 patients (tirzepatide: 47 [n = 995]; insulin glargine: 62 [n = 1 000]) experienced at least one adjudication confirmed MACE-4: The results showed that tirzepatide was not associated with excess risk for CV events compared with insulin glargine (HR: 0.74; CI: 0.51 to 1.08).

### Blood pressure

In the placebo-controlled phase 3 studies in adult patients with type 2 diabetes, treatment with tirzepatide resulted in a mean decrease in systolic and diastolic blood pressure of 6 to 9 mmHg and 3 to 4 mmHg, respectively. There was a mean decrease in systolic and diastolic blood pressure of 2 mmHg each in placebo treated patients.

### Other information

#### Fasting serum glucose

Across SURPASS-1 to -5 trials, treatment with tirzepatide resulted in significant reductions from baseline in FSG (changes from baseline to primary end point were -2.4 mmol/L to -3.8 mmol/L). Significant reductions from baseline in FSG could be observed as early as 2 weeks. Further improvement in FSG was seen through to 42 weeks then was sustained through the longest study duration of 104 weeks.

### Postprandial glucose

Across SURPASS-1 to -5 trials, treatment with tirzepatide resulted in significant reductions in mean 2 hour post prandial glucose (mean of 3 main meals of the day) from baseline (changes from baseline to primary end point were -3.35 mmol/L to -4.85 mmol/L).

### Triglycerides

Across SURPASS 1-5 trials, tirzepatide 5 mg, 10 mg and 15 mg resulted in reduction in serum triglyceride of 15-19 %, 18-27 % and 21-25 % respectively.

In the 40 week trial versus semaglutide 1 mg, tirzepatide 5 mg, 10 mg and 15 mg resulted in 19 %, 24 % and 25 % reduction in serum triglycerides levels respectively compared to 12 % reduction with semaglutide 1 mg.

### Proportion of patients reaching HbA1c < 5.7 % without clinically significant hypoglycaemia

In the 4 studies where tirzepatide was not combined with basal insulin (SURPASS-1 to -4), 93.6 % to 100 % of patients who achieved a normal glycaemia of HbA1c < 5.7 % ( $\leq 39$  mmol/mol), at the primary endpoint visit with tirzepatide treatment did so without clinically significant hypoglycaemia. In Study SURPASS-5, 85.9 % of patients treated with tirzepatide who reached HbA1c < 5.7 % ( $\leq 39$  mmol/mol) did so without clinically significant hypoglycaemia.

### Type 2 diabetes mellitus in children and adolescents aged 10 to less than 18 years

The safety and efficacy of tirzepatide 5 mg and 10 mg once weekly was evaluated in 99 patients aged 10 to below 18 years with type 2 diabetes on metformin (68.7 %) or basal insulin (8.1 %), or both (23.2 %), in a 30-week double-blind, placebo-controlled phase 3 study, followed by a 22-week open-label extension (SURPASS-PEDS). All participants had a body weight  $\geq 50$  kg and a BMI above the 85<sup>th</sup> percentile of the general age and gender-matched population for the country or region at study entry. In the open-label period, all participants on placebo were switched to tirzepatide at a maintenance dose of 5 mg while participants randomized to tirzepatide continued their treatment at the same dose of 5 or 10 mg.

At baseline, patients had a mean age of 14.7 years and 61 % were female. The mean duration of type 2 diabetes was 2.4 years. At 30 weeks, tirzepatide 5 mg and 10 mg, both pooled and individually, were superior to placebo in lowering HbA1c and reducing BMI. Glycemic efficacy was sustained and BMI reductions continued through Week 52.

**Table 7. SURPASS-PEDS: Results at week 30**


		<b>Tirzepatide 5 mg</b>	<b>Tirzepatide 10 mg</b>	<b>Tirzepatide Pooled</b>	<b>Placebo</b>
<b>mITT population (n)</b>		32	33	65	34
<b>HbA<sub>1c</sub> (%)</b>	Baseline (mean)	8.22	7.92	8.07	8.02
	Change from baseline	-2.16 <sup>###</sup>	-2.30 <sup>###</sup>	-2.23 <sup>###</sup>	0.049
	Difference from placebo [95 % CI]	-2.21** [-2.89, -1.53]	-2.35** [-3.03, -1.66]	-2.28** [-2.87, -1.69]	-
<b>HbA<sub>1c</sub> (mmol/mol)</b>	Baseline (mean)	66.3	63.1	64.7	64.2
	Change from baseline	-23.6 <sup>###</sup>	-25.1 <sup>###</sup>	-24.4 <sup>###</sup>	0.53

	Difference from placebo [95 % CI]	-24.2** [-31.6, -16.8]	-25.6** [-33.1, -18.2]	-24.9** [-31.4, -18.4]	-
<b>Patients (%) achieving HbA<sub>1c</sub></b>	< 7 %	84.2 <sup>††</sup>	91.5 <sup>††</sup>	87.9 <sup>††</sup>	34.3
	≤ 6.5 %	70.8**	86.1**	78.6**	27.8
	< 5.7 %	46.9 <sup>†</sup>	59.6 <sup>††</sup>	53.4 <sup>††</sup>	14.4
<b>FSG (mmol/L)</b>	Baseline (mean)	8.25	8.56	8.40	8.51
	Change from baseline	-1.94 <sup>##</sup>	-2.97 <sup>##</sup>	-2.46 <sup>##</sup>	-0.44
	Difference from placebo [95 % CI]	-1.50* [-2.71, -0.29]	-2.53** [-3.70, -1.36]	-2.02** [-3.05, -0.98]	-
<b>FSG (mg/dL)</b>	Baseline (mean)	148.6	154.2	151.4	153.3
	Change from baseline	-35.0 <sup>##</sup>	-53.5 <sup>##</sup>	-44.2 <sup>##</sup>	-7.93
	Difference from placebo [95 % CI]	-27.0* [-48.9, -5.2]	-45.6** [-66.7, -24.5]	-36.3** [-55.0, -17.6]	-
<b>BMI (kg/m<sup>2</sup>)</b>	Baseline (mean)	33.9	37.3	35.6	34.7
	Change (%) from baseline	-7.4 <sup>##</sup>	-11.2 <sup>##</sup>	-9.3 <sup>##</sup>	-0.4
	Difference (%) from placebo [95 % CI]	-7.0** [-10.48, -3.60]	-10.8** [-14.25, -7.39]	-8.9** [-11.91, -5.95]	-

\*p < 0.05, \*\*p < 0.001 for superiority, adjusted for multiplicity.

<sup>†</sup>p < 0.01, <sup>††</sup>p < 0.001 compared to placebo, not adjusted for multiplicity.

<sup>##</sup>p < 0.001 compared to baseline, not adjusted for multiplicity.



**Figure 6. Mean HbA<sub>1c</sub> (%) and % change in BMI from baseline to week 52**

### Weight management

The safety and efficacy of tirzepatide for weight management (weight reduction and maintenance) in combination with a reduced calorie intake and increased physical activity were evaluated in three randomised double-blinded, placebo-controlled phase 3 studies in patients without diabetes mellitus (SURMOUNT-1, SURMOUNT-3, SURMOUNT-4) and one randomised double-blinded, placebo-controlled phase 3 study in patients with diabetes mellitus (SURMOUNT-2). A total of 4 838 patients (3 588 treated with tirzepatide) were included in the trials.

In all 4 studies, all patients treated with tirzepatide started with 2.5 mg for 4 weeks. Then the dose of tirzepatide was increased by 2.5 mg every 4 weeks until they reached their assigned dose.

SURMOUNT-1 included a total of 2 539 patients (1 896 randomised to treatment with tirzepatide), while a total of 938 patients (623 randomised to treatment with tirzepatide) were included in SURMOUNT-2.

In SURMOUNT-1 the dose of tirzepatide or matching placebo was escalated to 5 mg, 10 mg, or 15 mg subcutaneously once weekly during a 20-week period followed by the maintenance period.

In SURMOUNT-2, the dose of tirzepatide or matching placebo was escalated to 10 mg or 15 mg subcutaneously once weekly during a 20-week period followed by the maintenance period.

SURMOUNT-3 included a total of 579 patients (287 randomised to treatment with tirzepatide). At the end of a 12-week intensive lifestyle intervention lead-in period, patients who achieved  $\geq 5.0\%$  weight reduction were randomised to a maximum tolerated dose (MTD) of Tirzepatide (10 or 15mg) or placebo once weekly for 72 weeks.

SURMOUNT-4 included a total of 782 patients. All patients entered the lead-in period (open label) and received tirzepatide treatment for 36 weeks to achieve MTD of 10 mg or 15 mg subcutaneously once weekly. At the end of the lead-in period, patients were randomised to continue treatment with tirzepatide once weekly (355 patients) or to switch to matching placebo for 52 weeks (double-blind phase).

Treatment with tirzepatide demonstrated clinically meaningful, statistically significant and sustained weight reduction compared with placebo in overweight patients ( $BMI \geq 27 \text{ kg/m}^2$  to  $< 30 \text{ kg/m}^2$ ) with at least one weight-related comorbidity and in patients with obesity ( $BMI \geq 30 \text{ kg/m}^2$ ). Furthermore, across the trials, a higher proportion of patients achieved  $\geq 5\%$ ,  $\geq 10\%$ ,  $\geq 15\%$  and  $\geq 20\%$  weight loss with tirzepatide compared with placebo. Treatment with tirzepatide also showed improvements in waist circumference, systolic blood pressure and lipid parameters compared to placebo.

In adult patients who are overweight or with obesity, treatment with tirzepatide produced a statistically significant reduction from baseline in body weight compared to placebo. A reduction in body weight was observed with tirzepatide irrespective of age, sex, race, ethnicity, baseline BMI, and glycemic status.

In addition, tirzepatide was studied in a 72-week, head-to-head trial with subcutaneous semaglutide. SURMOUNT-5 included a total of 751 patients. SURMOUNT-5 demonstrated that treatment with tirzepatide resulted in superior and clinically meaningful reduction in body weight compared to semaglutide.

The efficacy and safety of tirzepatide in moderate to severe obstructive sleep apnoea (OSA), in combination with diet and exercise, in patients with obesity were evaluated in two randomized double-blinded, placebo-controlled phase 3 studies (SURMOUNT-OSA Study 1 and Study 2). A total of 469 adult patients with moderate to severe OSA and obesity (234 randomised to treatment with tirzepatide) were included in these studies. Patients with type 2 diabetes mellitus were excluded. Study 1 enrolled patients unable or unwilling to use Positive Airway Pressure (PAP) therapy. Study 2 enrolled patients on PAP therapy. All patients were treated with the maximum tolerated dose (MTD; 10 mg or 15 mg) of tirzepatide or placebo, once weekly for 52 weeks.

In both studies, treatment with tirzepatide demonstrated statistically significant and clinically meaningful reduction in the apnoea-hypopnoea index (AHI) compared with placebo. A reduction in AHI was observed with tirzepatide irrespective of age, sex, ethnicity, baseline BMI or baseline OSA severity. Greater proportions of patients treated with tirzepatide achieved remission or mild non-symptomatic OSA compared to placebo (Table 13 and 14). Among tirzepatide treated patients, greater proportion of patients achieved at least 50 % AHI reduction compared to placebo.

### SURMOUNT-1

In a 72 week double blind placebo-controlled study, 2 539 adult patients with obesity (BMI  $\geq 30$  kg/m<sup>2</sup>), or with overweight (BMI  $\geq 27$  kg/m<sup>2</sup> to  $< 30$  kg/m<sup>2</sup>) and at least one weight-related comorbid condition, such as treated or untreated dyslipidaemia, hypertension, obstructive sleep apnoea, or cardiovascular disease, were randomised to tirzepatide 5 mg, 10 mg or 15 mg once weekly or placebo. Patients with type 2 diabetes mellitus were excluded. Patients had a mean age of 45 years and 67.5 % were women. At baseline 40.6 % of patients had prediabetes. Mean baseline body weight was 104.8 kg and mean BMI was 38 kg/m<sup>2</sup>.

Weight loss occurred early and continued throughout the trial. At end of treatment (week 72), the weight loss was superior and clinically meaningful compared with placebo (see table 8. and figure 7, showing results based on the efficacy estimand e.g. average treatment effect if participants had remained on their randomised treatment for the entire planned 72-week treatment duration). 89%, 96%, and 96% of patients in the 5 mg, 10 mg, and 15 mg tirzepatide groups, respectively, had a body weight reduction of 5% or more at 72 weeks, as compared with 28% of patients in the placebo group (P<0.001 for all comparisons with placebo). More patients in the tirzepatide groups had reductions in body weight of 10% or more, 15% or more, and 20% or more from baseline than patients in the placebo group (P<0.001).

**Table 8. SURMOUNT-1: Results at week 72**

	<b>Tirzepatide 5 mg</b>	<b>Tirzepatide 10 mg</b>	<b>Tirzepatide 15 mg</b>	<b>Placebo</b>
<b>mITT population (n)</b>	630	636	630	643
<b>Body weight</b>				
Baseline (kg)	102.9	105.9	105.5	104.8
Change (%) from baseline	-16.0 <sup>†††</sup>	-21.4 <sup>†††</sup>	-22.5 <sup>†††</sup>	-2.4 <sup>†††</sup>
Difference (%) from placebo [95% CI]	-13.5 <sup>***</sup> [-14.6, -12.5]	-18.9 <sup>***</sup> [-20.0, -17.8]	-20.1 <sup>***</sup> [-21.2, -19.0]	-
Change (kg) from baseline	-16.1 <sup>†††</sup>	-22.2 <sup>†††</sup>	-23.6 <sup>†††</sup>	-2.4 <sup>†††</sup>
Difference (kg) from placebo [95% CI]	-13.8 <sup>###</sup> [-15.0, -12.6]	-19.8 <sup>###</sup> [-21.0, -18.6]	-21.2 <sup>###</sup> [-22.4, -20.0]	-
<b>Patients (%) achieving body weight reduction</b>				
$\geq 5\%$	89.4 <sup>***</sup>	96.2 <sup>***</sup>	96.3 <sup>***</sup>	27.9
$\geq 10\%$	73.4 <sup>###</sup>	85.9 <sup>***</sup>	90.1 <sup>***</sup>	13.5
$\geq 15\%$	50.2 <sup>###</sup>	73.6 <sup>***</sup>	78.2 <sup>***</sup>	6.0
$\geq 20\%$	31.6 <sup>###</sup>	55.5 <sup>***</sup>	62.9 <sup>***</sup>	1.3
<b>Waist circumference (cm)</b>				
Baseline	113.2	114.9	114.4	114.0


Change from baseline	-14.6 <sup>†††</sup>	-19.4 <sup>†††</sup>	-19.9 <sup>†††</sup>	-3.4 <sup>†††</sup>
Difference from placebo [95% CI]	-11.2 <sup>###</sup> [-12.3, -10.0]	-16.0 <sup>***</sup> [-17.2, -14.9]	-16.5 <sup>***</sup> [-17.7, -15.4]	-
<b>Systolic blood pressure (mmHg)</b>				
Baseline	123.6	123.8	122.9	122.8
Change from baseline	-7.4 <sup>†††</sup>	-8.8 <sup>†††</sup>	-8.0 <sup>†††</sup>	-1.3 <sup>††</sup>
Difference from placebo [95% CI]	-6.1 <sup>###</sup> [-7.4, -4.8]	-7.5 <sup>###</sup> [-8.8, -6.2]	-6.7 <sup>###</sup> [-8.0, -5.4]	-
<b>Diastolic blood pressure (mmHg)</b>				
Baseline	79.2	79.9	79.3	79.5
Change from baseline	-5.3 <sup>†††</sup>	-5.8 <sup>†††</sup>	-4.7 <sup>†††</sup>	-1.0 <sup>††</sup>
Difference from placebo [95% CI]	-4.3 <sup>###</sup> [-5.3, -3.4]	-4.8 <sup>###</sup> [-5.7, -3.8]	-3.7 <sup>###</sup> [-4.7, -2.8]	-
<b>Total Cholesterol (mmol/L)</b>				
Baseline	4.8	4.9	4.9	4.8
Change (%) from baseline	-5.0 <sup>†††</sup>	-5.7 <sup>†††</sup>	-7.5 <sup>†††</sup>	-1.2
Difference (%) from placebo [95% CI]	-3.9 <sup>###</sup> [-5.7, -2.1]	-4.6 <sup>###</sup> [-6.4, -2.7]	-6.4 <sup>###</sup> [-8.2, -4.6]	-
<b>Triglycerides (mmol/L)</b>				
Baseline	1.5	1.4	1.4	1.5
Change (%) from baseline	-24.3 <sup>†††</sup>	-27.0 <sup>†††</sup>	-31.4 <sup>†††</sup>	-6.3 <sup>†††</sup>
Difference (%) from placebo [95% CI]	-19.3 <sup>###</sup> [-22.8, -15.6]	-22.1 <sup>###</sup> [-25.5, -18.5]	-26.7 <sup>###</sup> [-29.9, -23.4]	-
<b>non-HDL (mmol/L)</b>				
Baseline	3.6	3.6	3.6	3.6
Change (%) from baseline	-9.6 <sup>†††</sup>	-11.0 <sup>†††</sup>	-13.5 <sup>†††</sup>	-1.8 <sup>†</sup>
Difference (%) from placebo [95% CI]	-7.9 <sup>###</sup> (-10.1, -5.7)	-9.3 <sup>###</sup> (-11.4, -7.1)	-11.9 <sup>###</sup> (-13.9, -9.7)	-
<b>LDL (mmol/L)</b>				
Baseline	2.8	2.9	2.8	2.8
Change (%) from baseline	-5.3 <sup>†††</sup>	-6.6 <sup>†††</sup>	-8.6 <sup>†††</sup>	-0.9
Difference (%) from placebo [95% CI]	-4.5 <sup>##</sup> [-7.3, -1.7]	-5.8 <sup>###</sup> [-8.5, -3.0]	-7.8 <sup>###</sup> [-10.5, -5.8]	-
<b>HDL (mmol/L)</b>				
Baseline	1.2	1.2	1.2	1.2
Change (%) from baseline	7.0 <sup>†††</sup>	8.6 <sup>†††</sup>	8.2 <sup>†††</sup>	0.2
Difference (%) from placebo [95% CI]	6.7 <sup>###</sup> [4.6, 8.9]	8.3 <sup>###</sup> [6.1, 10.6]	7.9 <sup>###</sup> [5.8, 10.2]	-
<b>HbA1c (%)</b>				
Baseline	5.6	5.6	5.6	5.6
Change from baseline	-0.4 <sup>†††</sup>	-0.5 <sup>†††</sup>	-0.5 <sup>†††</sup>	-0.1 <sup>†††</sup>
Difference from placebo [95% CI]	-0.3 <sup>###</sup> [-0.4, -0.3]	-0.4 <sup>###</sup> [-0.5, -0.4]	-0.4 <sup>###</sup> [-0.5, -0.4]	-
<b>HbA1c (mmol/mol)</b>				
Baseline	37.2	37.1	37.1	37.4
Change from baseline	-4.4 <sup>†††</sup>	-5.3 <sup>†††</sup>	-5.6 <sup>†††</sup>	-0.8 <sup>†††</sup>
Difference from placebo	-3.6 <sup>###</sup>	-4.6 <sup>###</sup>	-4.8 <sup>###</sup>	-

[95% CI]	[-4.0, -3.2]	[-4.9, -4.2]	[-5.2, -4.5]
----------	--------------	--------------	--------------

## pValue < 0.01, ### pvalue < 0.001 versus placebo, not adjusted for multiplicity.

\*\*\* pValue < 0.001 versus placebo, adjusted for multiplicity.

† p-Value < 0.05, †† p value < 0.01, ††† p value < 0.001 versus baseline.



**Figure 7. Mean change in body weight (%) from baseline to week 72**

Among the patients in SURMOUNT-1 with prediabetes at baseline (N = 1032), 95.3% patients treated with tirzepatide reverted to normoglycemia at week 72, as compared with 61.9% of patients in the placebo group.

### SURMOUNT-2

In a 72-week double blind placebo-controlled study, 938 adult patients with BMI  $\geq 27$  kg/m<sup>2</sup> and type 2 diabetes mellitus, were randomised to tirzepatide 10 mg or 15 mg once weekly or placebo. Patients had a mean age of 54 years and 50.7% were women. Mean baseline body weight was 100.7 kg and mean BMI was 36.1 kg/m<sup>2</sup>.

Weight loss occurred early and continued throughout the trial. At end of treatment (week 72), the weight loss was superior and clinically meaningful compared with placebo (see table 9 and figure 8, showing results based on the efficacy estimand e.g. average treatment effect if participants had remained on their randomised treatment for the entire planned 72-week treatment duration). 81.6% and 86.4% of patients in the 10 mg, and 15 mg tirzepatide groups, respectively, had a body weight reduction of 5% or more at 72 weeks, as compared with 30.6% of patients in the placebo group (P < 0.001 for all comparisons with placebo). More patients in the tirzepatide groups had reductions in body weight of 10% or more, 15% or more, and 20% or more from baseline than patients in the placebo group (P < 0.001).

**Table 9. SURMOUNT-2: Results at week 72**

	<b>Tirzepatide 10 mg</b>	<b>Tirzepatide 15 mg</b>	<b>Placebo</b>
<b>mITT population (n)</b>	312	311	315
<b>Body weight</b>			
Baseline (kg)	101.1	99.5	101.7
Change (%) from baseline	-13.4 <sup>†††</sup>	-15.7 <sup>†††</sup>	-3.3 <sup>†††</sup>
Difference (%) from placebo [95% CI]	-10.1 <sup>***</sup> [-11.5, -8.8]	-12.4 <sup>***</sup> [-13.7, -11.0]	-
Change (kg) from baseline	-13.5 <sup>†††</sup>	-15.6 <sup>†††</sup>	-3.2 <sup>†††</sup>
Difference (kg) from placebo [95% CI]	-10.3 <sup>***</sup> [-11.7, -8.8]	-12.4 <sup>***</sup> [-13.8, -11.0]	-
<b>Patients (%) achieving body weight reduction</b>			
≥ 5%	81.6 <sup>***</sup>	86.4 <sup>***</sup>	30.6
≥ 10%	63.4 <sup>***</sup>	69.6 <sup>***</sup>	8.7
≥ 15%	41.4 <sup>***</sup>	51.8 <sup>***</sup>	2.6
≥ 20%	23.0 <sup>***</sup>	34.0 <sup>***</sup>	1.0
<b>Waist circumference (cm)</b>			
Baseline	114.3	114.6	116.1
Change from baseline	-11.2 <sup>†††</sup>	-13.8 <sup>†††</sup>	-3.4 <sup>†††</sup>
Difference from placebo [95% CI]	-7.8 <sup>***</sup> [-9.2, -6.4]	-10.4 <sup>***</sup> [-11.8, -8.9]	-
<b>Systolic blood pressure (mmHg)</b>			
Baseline	130.6	130.0	131.1
Change from baseline	-6.1 <sup>†††</sup>	-8.2 <sup>†††</sup>	-1.0
Difference from placebo [95% CI]	-5.2 <sup>###</sup> [-7.2, -3.1]	-7.3 <sup>###</sup> [-9.3, -5.2]	
<b>Diastolic blood pressure (mmHg)</b>			
Baseline	80.2	79.7	79.4
Change from baseline	-2.2 <sup>†††</sup>	-2.9 <sup>†††</sup>	-0.2
Difference from placebo [95% CI]	-2.0 <sup>##</sup> [-3.3, -0.8]	-2.7 <sup>###</sup> [-4.0, -1.5]	
<b>Total Cholesterol (mmol/L)</b>			
Baseline	4.5	4.3	4.5
Change (%) from baseline	-3.0 <sup>††</sup>	-2.2 <sup>†</sup>	2.1
Difference (%) from placebo [95% CI]	-5.0 <sup>##</sup> [-7.8, -2.0]	-4.2 <sup>##</sup> [-7.1, -1.2]	
<b>Triglycerides (mmol/L)</b>			
Baseline	1.8	1.8	1.9
Change (%) from baseline	-26.8 <sup>†††</sup>	-30.6 <sup>†††</sup>	-5.8 <sup>†</sup>
Difference (%) from placebo [95% CI]	-22.2 <sup>###</sup> [-27.3, -16.8]	-26.3 <sup>###</sup> [-31.1, -21.0]	
<b>non-HDL (mmol/L)</b>			
Baseline	3.3	3.2	3.4


Change (%) from baseline	-6.6 <sup>†††</sup>	-6.7 <sup>†††</sup>	2.3
Difference (%) from placebo [95% CI]	-8.7 <sup>###</sup> (-12.5, -4.8]	-8.8 <sup>###</sup> [-12.6, -4.8]	
<b>LDL (mmol/L)</b>			
Baseline	2.3	2.2	2.4
Change (%) from baseline	2.3	3.2	6.3 <sup>†††</sup>
Difference (%) from placebo [95% CI]	-3.7 [-8.3, 1.0]	-3.0 [-7.6, 1.9]	
<b>HDL (mmol/L)</b>			
Baseline	1.1	1.1	1.1
Change (%) from baseline	6.9 <sup>†††</sup>	9.6 <sup>†††</sup>	1.1
Difference (%) from placebo [95% CI]	5.7 <sup>###</sup> [2.7, 8.7]	8.4 <sup>###</sup> [5.3, 11.6]	
<b>HbA1c (%)</b>			
Baseline	8.0	8.1	8.0
Change from baseline	-2.1 <sup>†††</sup>	-2.2 <sup>†††</sup>	-0.2 <sup>†</sup>
Difference from placebo [95% CI]	-2.0 <sup>***</sup> [-2.2, -1.8]	-2.1 <sup>***</sup> [-2.2, -1.9]	
<b>HbA1c (mmol/mol)</b>			
Baseline	64.1	64.7	63.4
Change from Baseline	-23.4 <sup>†††</sup>	-24.3 <sup>†††</sup>	-1.8 <sup>†</sup>
Difference from placebo [95% CI]	-21.6 <sup>***</sup> [-23.5, -19.6]	-22.5 <sup>***</sup> [-24.4, -20.6]	

<sup>##</sup>p-Value < 0.01, <sup>###</sup>p-value < 0.001 versus placebo, not adjusted for multiplicity.

<sup>\*\*\*</sup>p-Value < 0.001 versus placebo, adjusted for multiplicity.

<sup>†</sup>p-Value < 0.05, <sup>††</sup>p value < 0.01, <sup>†††</sup>p value < 0.001 versus baseline.

During the trial, treatment was permanently discontinued by 9.3 % and 13.8 % of patients randomised to tirzepatide 10 mg and 15 mg respectively compared to 14.9 % randomised to placebo.



**Figure 8. Mean change in body weight (%) from baseline to week 72**

In SURMOUNT-2 pooled doses of tirzepatide 10 mg and 15 mg led to a significant improvement compared to placebo in systolic blood pressure (-7.2 mmHg vs. -1.0 mmHg), triglycerides (-28.6 % vs. -5.8 %), non-HDL-C (-6.6 % vs. 2.3 %), and HDL-C (8.2 % vs. 1.1 %).

### SURMOUNT-3

In an 84 week study, 806 adult patients with obesity ( $BMI \geq 30 \text{ kg/m}^2$ ) or with overweight ( $BMI \geq 27 \text{ kg/m}^2$  to  $< 30 \text{ kg/m}^2$ ) and at least one weight related comorbid condition, such as treated or untreated dyslipidaemia, hypertension, obstructive sleep apnoea, or cardiovascular disease, entered a 12-week intensive lifestyle intervention lead-in period consisting of a low calorie diet (1 200-1 500 kcal/day), increased physical activity and frequent behavioural counselling. Patients with type 2 diabetes mellitus were excluded. At the end of the 12-week lead-in period, 579 patients who achieved  $\geq 5.0 \%$  weight reduction were randomised to tirzepatide maximum tolerated dose (MTD) of 10 mg or 15 mg once weekly or to placebo, for 72 weeks (double-blind phase). Patients treated with tirzepatide started with 2.5 mg for 4 weeks. The dose of tirzepatide was increased by 2.5 mg every 4 weeks until patients reached their MTD. Patients were on a reduced-calorie diet and increased physical activity throughout the double-blind phase of the study. At randomisation patients had a mean age of 46 years and 63 % were women. Mean baseline body weight at randomisation was 101.9 kg and mean BMI was  $35.9 \text{ kg/m}^2$ .

**Table 10. SURMOUNT-3: Results at week 72**


	<b>Tirzepatide MTD</b>	<b>Placebo</b>
<b>mITT population (n)</b>	287	292
<b>Body weight</b>		
Baseline <sup>1</sup> (kg)	102.3	101.3
Change (%) from baseline <sup>1</sup>	-21.1 <sup>††</sup>	3.3 <sup>††</sup>
Difference (%) from placebo [95 % CI]	-24.5 <sup>**</sup> [-26.1, -22.8]	-
Change (kg) from baseline <sup>1</sup>	-21.5 <sup>††</sup>	3.5 <sup>††</sup>
Difference (kg) from placebo [95 % CI]	-25.0 <sup>##</sup> [-26.9, -23.2]	-
<b>Patients (%) achieving body weight reduction</b>		
≥ 5 %	94.4 <sup>**</sup>	10.7
≥ 10 %	88.0 <sup>**</sup>	4.8
≥ 15 %	73.9 <sup>**</sup>	2.1
≥ 20 %	54.9 <sup>**</sup>	1.0
<b>Patients (%) who maintain ≥80% of the body weight lost during the 12-week lead-in period</b>	98.6 <sup>**</sup>	37.8
<b>Waist circumference (cm)</b>		
Baseline <sup>1</sup>	109.2	109.6
Change from baseline <sup>1</sup>	-16.8 <sup>††</sup>	1.1
Difference from placebo [95 % CI]	-17.9 <sup>**</sup> [-19.5, -16.3]	-

<sup>1</sup>Randomisation (Week 0)

<sup>††</sup>p < 0.001 versus baseline<sup>1</sup>.

<sup>\*\*</sup>p < 0.001 versus placebo, adjusted for multiplicity.

<sup>##</sup>p < 0.001 versus placebo, not adjusted for multiplicity.



**Figure 9. Mean change in body weight (%) from Week -12 to week 72**

*SURMOUNT-4*

In an 88 week study, 783 adult patients with obesity ( $BMI \geq 30 \text{ kg/m}^2$ ) or with overweight ( $BMI \geq 27 \text{ kg/m}^2$  to  $< 30 \text{ kg/m}^2$ ) and at least one weight related comorbid condition, such as treated or untreated dyslipidaemia, hypertension, obstructive sleep apnoea, or cardiovascular disease, were enrolled. Patients with type 2 diabetes mellitus were excluded. All patients received tirzepatide treatment for 36 weeks to achieve MTD of 10 mg or 15 mg (open label lead-in phase). Patients started with 2.5 mg dose of tirzepatide for 4 weeks and the dose was increased by 2.5 mg every 4 weeks until patients reached their MTD. At the start of lead-in period patients had a mean body weight of 107.0 kg and a mean BMI of  $38.3 \text{ kg/m}^2$ . At the end of the lead-in period, 670 patients who achieved tirzepatide MTD of 10 mg or 15 mg dose were randomised to continue treatment with tirzepatide once weekly or to switch to placebo for 52 weeks (double-blind phase). Patients were counselled on a reduced calorie diet and increased physical activity throughout the trial. At randomisation (week 36), patients had a mean age of 49 years and 71 % were women. Mean body weight at randomisation was 85.2 kg and mean BMI was  $30.5 \text{ kg/m}^2$ .

Patients who continued treatment with tirzepatide for an additional 52 weeks (up to 88 weeks in total) maintained and experienced further weight loss after the initial weight reduction achieved during the 36 week lead-in phase. The weight reduction was superior and clinically meaningful compared to the placebo group, in which a substantial regain of body weight lost during the lead-in phase was observed (see Table 11 and Figure 10). Nevertheless, the observed mean body weight for placebo-treated patients was lower at week 88 than at the start of the lead-in phase (see Figure 10).


**Table 11. SURMOUNT-4: Results at week 88**

	<b>Tirzepatide MTD</b>	<b>Placebo</b>
<b>mITT population (n) only patients at Week 36</b>	335	335
<b>Body weight</b>		
Weight (kg) at Week 0 (baseline)	106.7	107.8
Weight (kg) at Week 36 (randomisation)	84.5	85.9
Change (%) from Week 36 at Week 88	-6.7 <sup>††</sup>	14.8 <sup>††</sup>
Difference (%) from placebo at Week 88 [95 % CI]	-21.4 <sup>**</sup> [-22.9, -20.0]	-
Change (kg) from Week 36 at Week 88	-5.7 <sup>††</sup>	11.9 <sup>††</sup>
Difference (kg) from placebo at Week 88 [95 % CI]	-17.6 <sup>##</sup> [-18.8, -16.4]	-
<b>Patients (%) achieving body weight reduction from Week 0 to Week 88</b>		
≥ 5 %	98.5 <sup>**</sup>	69.0
≥ 10 %	94.0 <sup>**</sup>	44.4
≥ 15 %	87.1 <sup>**</sup>	24.0
≥ 20 %	72.6 <sup>**</sup>	11.6
<b>Patients (%) who maintain ≥80% of the body weight lost during the 36-week lead-in period at Week 88</b>	93.4 <sup>**</sup>	13.5
<b>Waist circumference (cm)</b>		
Baseline (Week 0)	114.9	115.6
Randomisation (Week 36)	96.7	98.2
Change from randomisation (Week 36)	-4.6 <sup>††</sup>	8.3 <sup>††</sup>
Difference from placebo [95 % CI]	-12.9 <sup>**</sup> [-14.1, -11.7]	-

<sup>††</sup>p < 0.001 versus baseline.

<sup>\*\*</sup>p < 0.001 versus placebo, adjusted for multiplicity.

<sup>##</sup>p < 0.001 versus placebo, not adjusted for multiplicity.



**Figure 10. Mean change in body weight (%) from baseline (Week 0) to week 88**

**Risk of weight regain to > 95 % of study baseline (Week 0) weight at week 88**

Time to event analysis showed that continued tirzepatide treatment during the double-blind period reduced the risk of returning to greater than 95 % body weight observed at Week 0, for those who had already lost at least 5 % since week 0 by approximately 99 % compared with placebo (hazard ratio, 0.013 [95 % CI, 0.004 to 0.046];  $p < 0.001$ ).

*SURMOUNT-5*

In a 72-week study, 751 adult patients with obesity (BMI  $\geq 30$  kg/m<sup>2</sup>) or overweight (BMI  $\geq 27$  kg/m<sup>2</sup> to  $< 30$  kg/m<sup>2</sup>) with at least 1 weight-related comorbid condition were randomised to tirzepatide 15 mg or semaglutide 2.4 mg once weekly. When patients did not tolerate this dose, the dose was reduced to tirzepatide 10 mg or semaglutide 1.7 mg once weekly. Patients were counselled on a reduced calorie diet and increased physical activity throughout the trial. Participants had a mean age of 44.7 years and a mean BMI of 39.4 kg/m<sup>2</sup>. Overall, 64.7 % were female.

Treatment with tirzepatide for 72 weeks resulted in a superior and clinically meaningful reduction in body weight compared to semaglutide. The percent change from baseline at week 72 (primary endpoint) was -21.6 % for tirzepatide and -15.4 % for semaglutide (difference from semaglutide: -6.2 %; 95 % CI [-7.8, -4.6];  $p < 0.001$ ). Tirzepatide also achieved superiority compared with semaglutide for the key secondary endpoints, i.e. proportion of patients achieving  $\geq 10$  %,  $\geq 15$  %,  $\geq 20$  %, and  $\geq 25$  % body weight reduction at week 72 as well as reduction of waist circumference at week 72.

### Cardiovascular evaluation

In SURMOUNT-1, -2 and -3 phase 3 studies, a total of 27 participants experienced at least one adjudication confirmed MACE (TZP: 17 (n = 2 806); placebo: 10 (n = 1 250)); the event rate was similar across placebo and tirzepatide.

### Blood pressure

In SURMOUNT-1, -2 and -3 phase 3 studies, treatment with tirzepatide resulted in a mean decrease in systolic and diastolic blood pressure of 7 mmHg and 4 mmHg, respectively. There was a mean decrease in systolic and diastolic blood pressure of < 1 mmHg each in placebo treated patients.

### Triglycerides

In SURMOUNT-1 placebo-controlled phase 3 study patients with obesity or overweight without type 2 diabetes mellitus, treatment with tirzepatide 5 mg, 10 mg, and 15 mg resulted in 24 %, 27 % and 31 % reduction in serum triglyceride levels respectively compared to 6 % reduction with placebo.

In SURMOUNT-2 placebo-controlled phase 3 study in patients with obesity or overweight with type 2 diabetes mellitus, treatment with tirzepatide 10 mg and 15 mg resulted in 27 % and 31 % reduction in serum triglyceride levels respectively compared to 6 % reduction with placebo.

### Other information

#### Changes in body composition

Changes in body composition were evaluated in a sub-study in SURMOUNT-1 using dual energy X-ray absorptiometry (DEXA). The results of the DEXA assessment showed that treatment with tirzepatide was accompanied by greater reduction in fat mass than in lean body mass leading to an improvement in body composition compared to placebo after 72 weeks. Furthermore, this reduction in total fat mass was accompanied by a reduction in visceral fat. These results suggest that most of the total weight loss was attributable to a reduction in fat tissue, including visceral fat.

### Patient Reported Outcomes

In SURMOUNT-1, -2, -3 and -4, patient-reported outcomes, including aspects of physical and psychosocial functioning, were assessed via patient self-report using the Short Form-36 health survey (SF-36v2) acute form and the obesity-specific questionnaire, Impact of Weight on Quality of Life-Lite-Clinical Trial version (IWQOL-Lite-CT).

Weight reduction with tirzepatide was accompanied by improvements in aspects of patient reported mental and physical health as assessed by the SF-36v2 acute form and IWQOL-Lite-CT in patients with obesity or overweight, with or without type 2 diabetes mellitus.

### SF-36v2:

In SURMOUNT-1, tirzepatide demonstrated improvements from baseline as compared to placebo in all eight domains of the SF-36v2 (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health), and the Physical Component Summary, and Mental Component Summary scores. This included a

statistically significant and clinically relevant improvement from baseline for tirzepatide (pooled doses of 10 mg and 15 mg) as compared to placebo in Physical Functioning domain score (See table 12).

In SURMOUNT-2, tirzepatide 10 and 15 mg showed improvements compared with placebo for the SF-36v2 Physical Functioning and General Health domain scores, as well as the Physical Component Summary score. The tirzepatide 15-mg group also showed an improvement compared with placebo for the Bodily Pain, Vitality, and Social Functioning domain scores.

In SURMOUNT-3, tirzepatide MTD showed improvements compared with placebo in all eight domains of the SF-36v2, and the Physical Component Summary scores.

In SURMOUNT-4, from randomization (Week 36) to Week 88, tirzepatide MTD showed improvements compared with placebo in all eight domains of the SF-36v2, and the Physical Component Summary and Mental Component Summary scores.

**Table 12. SURMOUNT-1: Change from Baseline in SF-36v2 Physical Functioning domain at Week 72.**

Parameters	<b>Tirzepatide Pooled doses (10mg &amp; 15 mg) (N=1266)</b>	<b>Placebo (N=643)</b>
n	1080	482
Baseline	49.6	49.7
Change from baseline	4.0 <sup>†††</sup>	1.7 <sup>†††</sup>
Difference (%) from placebo [95% CI]	2.3 <sup>***</sup> [1.6, 2.9]	-

\*\*\* *P* value vs placebo < 0.001

††† *P* value vs baseline < 0.001

#### IWQOL-Lite-CT:

Beneficial effects of tirzepatide were also demonstrated in SURMOUNT-1, -2, -3 and -4 in the composites (Physical Function, Physical, and Psychosocial) and the total scores of the IWQOL-Lite-CT.

#### SURMOUNT-OSA, Study 1

In a 52 week double-blind placebo-controlled study, 234 adult patients with moderate to severe OSA and obesity, were randomised to tirzepatide MTD of 10 mg or 15 mg once weekly, or to placebo, once weekly. Patients had a mean age of 48 years, 33 % were female, 35 % had moderate OSA, 63 % had severe OSA, 65 % had pre-diabetes, 76 % had hypertension, 10 % had cardiac disorders, and 81 % had dyslipidemia. Patients had a mean Epworth Sleepiness Scale (ESS) of 10.5.

**Table 13. SURMOUNT-OSA, Study 1: Results at week 52**


	<b>Tirzepatide MTD</b>	<b>Placebo</b>
<b>mITT population (n)</b>	114	120
<b>AHI (events/hr)</b>		
Baseline mean	54.3	50.9
Change from baseline	-27.4 <sup>††</sup>	-4.8 <sup>†</sup>
Difference from placebo [95 % CI]	-22.5 <sup>**</sup> [-28.7, -16.4]	-
<b>% Change in AHI</b>		
% Change from baseline	-55.0 <sup>††</sup>	-5.0
% Difference from placebo [95% CI]	-49.9 <sup>**</sup> [-62.8, -37.0]	-
<b>Patients (%) achieving reduction in AHI</b>		
≥50%	62.3	19.2
% Difference from placebo [95% CI]	43.6 <sup>**</sup> [31.1, 56.2]	-
<b>Remission or mild non-symptomatic OSA</b>		
% of Patients with AHI <5 or AHI 5-14 and ESS≤10	43.0	14.9
% Difference from placebo [95% CI]	30.6 <sup>**</sup> [19.8, 41.4]	-
<b>Sleep apnoea-specific hypoxic burden (% min/h)<sup>a</sup></b>		
Baseline geometric mean	156.6	148.2
% Change from baseline	-67.6 <sup>††</sup>	-13.8
Relative difference from placebo [95% CI]	-62.4 <sup>**</sup> [-70.6, -51.9]	-
<b>Body weight (kg)</b>		
Baseline mean	117.0	112.7
% Change from baseline	-18.1 <sup>††</sup>	-1.3
% Difference from placebo [95% CI]	-16.8 <sup>**</sup> [-18.8, -14.7]	-
<b>Systolic Blood Pressure (mmHg)<sup>b</sup></b>		
Baseline mean	128.2	130.3
Change from baseline	-9.6 <sup>††</sup>	-1.7
Difference from placebo [95% CI]	-7.9 <sup>**</sup> [-11.0, -4.9]	-
<b>hsCRP (mg/L)<sup>a</sup></b>		
Baseline geometric mean	3.6	3.8
% Change from baseline	-44.2 <sup>††</sup>	-21.4 <sup>†</sup>
Relative difference from placebo [95% CI]	-28.9 <sup>*</sup> [-43.4, -10.8]	-

† p < 0.05, †† p < 0.001 versus baseline.

\* p < 0.05, \*\* p < 0.001 versus placebo, adjusted for multiplicity.

<sup>a</sup> Analysed using log transformed data.

<sup>b</sup> Blood pressure was assessed at Week 48 because PAP withdrawal at Week 52 may confound blood pressure assessment.



**Figure 11. Change from Baseline in Apnoea-Hypopnea Index (AHI) to Week 52 in SURMOUNT-OSA, Study 1**

In SURMOUNT-OSA, Study 1, tirzepatide MTD led to a significant improvement compared to placebo in diastolic blood pressure (-5.2 mmHg vs. -2.0 mmHg), triglycerides (-32.9 % vs. -1.0 %), non-HDL-C (-15.0 % vs. -2.3 %), HDL-C (10.6 % vs. 3.1 %), and fasting insulin (-44.2 % vs. -4.7 %).

#### SURMOUNT-OSA, Study 2

In a 52 week double-blind placebo-controlled study, 235 adult patients with moderate to severe OSA and obesity, were randomised to tirzepatide MTD of 10 mg or 15 mg once weekly or to placebo, once weekly. Patients had a mean age of 52 years, 28 % were female, 31 % had moderate OSA, 68 % had severe OSA, 65 % had pre-diabetes, 77 % had hypertension, 11 % had cardiac disorders, and 84 % had dyslipidemia. Patients had a mean ESS of 10.0.

**Table 14. SURMOUNT-O SA, Study 2: Results at week 52**


	<b>Tirzepatide MTD</b>	<b>Placebo</b>
<b>mITT population (n)</b>	119	114
<b>AHI (events/hr)</b>		
Baseline mean	45.8	53.1
Change from baseline	-30.4 <sup>††</sup>	-6.0 <sup>†</sup>
Difference from placebo [95 % CI]	-24.4 <sup>**</sup> [-30.3, -18.6]	-
<b>% Change in AHI</b>		
% Change from baseline	-62.8 <sup>††</sup>	-6.4
% Difference from placebo [95% CI]	-56.4 <sup>**</sup> [-70.7, -42.2]	-
<b>Patients (%) achieving reduction in AHI</b>		
≥50%	74.3	22.9
% Difference from placebo [95% CI]	50.8 <sup>**</sup> [38.6, 62.9]	-
<b>Remission or mild non-symptomatic OSA</b>		
% of Patients with AHI <5 or AHI 5-14 and ESS≤10	51.5	13.6
% Difference from placebo [95% CI]	35.1 <sup>**</sup> [23.8, 46.4]	-
<b>Sleep apnoea-specific hypoxic burden (% min/h)<sup>a</sup></b>		
Baseline geometric mean	129.9	139.1
% Change from baseline	-76.9 <sup>††</sup>	-30.4 <sup>†</sup>
Relative difference from placebo [95% CI]	-66.8 <sup>**</sup> [-76.5, -53.1]	-
<b>Body weight (kg)</b>		
Baseline mean	115.8	115.0
% Change from baseline	-20.1 <sup>††</sup>	-2.3 <sup>†</sup>
% Difference from placebo [95% CI]	-17.8 <sup>**</sup> [-19.9, -15.7]	-
<b>Systolic Blood Pressure (mmHg)<sup>b</sup></b>		
Baseline mean	130.7	130.5
Change from baseline	-7.6 <sup>††</sup>	-3.3 <sup>†</sup>
Difference from placebo [95% CI]	-4.3 <sup>*</sup> [-7.3, -1.2]	-
<b>hsCRP (mg/L)<sup>a</sup></b>		
Baseline geometric mean	3.0	2.7
% Change from baseline	-50.7 <sup>††</sup>	-10.4
Relative difference from placebo [95% CI]	-45.1 <sup>**</sup> [-58.8, -26.7]	-

† p < 0.05, †† p < 0.001 versus baseline.

\* p < 0.05, \*\* p < 0.001 versus placebo, adjusted for multiplicity.

<sup>a</sup> Analysed using log transformed data.

<sup>b</sup> Blood pressure was assessed at Week 48 because PAP withdrawal at Week 52 may confound blood pressure assessment.



**Figure 12. Change from Baseline in Apnoea-Hypopnea Index (AHI) to Week 52 in SURMOUNT-OSA, Study 2**

In SURMOUNT-OSA, Study 2, tirzepatide MTD led to a significant improvement compared to placebo in triglycerides (-35.2 % vs. -5.4 %), non-HDL-C (-15.8 % vs. -1.8 %), HDL-C (15.0 % vs. 4.5 %), and fasting insulin (-48.5 % vs. -5.6 %).

#### Improvement in sleep-related impairment and sleep disturbance

Tirzepatide-treated patients, pooled across Studies 1 and 2, demonstrated statistically significant improvement in sleep-related impairment and sleep disturbance, as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment short form 8a (PROMIS SRI); t-scores (-7.3) versus placebo (-3.5) and PROMIS sleep disturbance short form 8b (PROMIS SD); t-scores (-5.8) versus placebo (-2.9), respectively. This trend was consistent in the individual studies. A significantly greater proportion of patients treated with tirzepatide reported a meaningful within-patient change compared to placebo in PROMIS SRI (Study 1: 44.4 % vs 26.6 %; Study 2: 39.1 % v 23.1 %) and PROMIS SD (Study 1: 35.8 % vs 24.8 %; Study 2: 46.1 % vs 27.2 %).

#### Cardiovascular evaluation

In two placebo-controlled OSA phase 3 studies, one patient experienced at least one adjudication confirmed MACE (tirzepatide: 0 (n = 233); placebo: 1 (n = 234)).

### *Blood pressure*

In two placebo-controlled OSA phase 3 studies, treatment with tirzepatide resulted in a mean decrease in systolic and diastolic blood pressure of 9.0 mmHg and 3.8 mmHg, respectively. There was a mean decrease in systolic and diastolic blood pressure of 2.5 mmHg and 1.0 mmHg, respectively, in placebo treated patients.

### Other information

#### *Triglycerides*


In two placebo-controlled OSA phase 3 studies (Study 1 and Study 2, respectively), treatment with tirzepatide MTD (10 mg or 15 mg) resulted in 32.9 % and 35.2 % reduction in serum triglyceride levels compared to 1.0 % and 5.4 % reduction with placebo.

#### *Heart failure with preserved ejection fraction*

The efficacy and safety of tirzepatide for the treatment of chronic heart failure (New York Heart Association [NYHA] II-IV) with left ventricular ejection fraction  $\geq 50\%$  were evaluated in a randomized, double-blinded, placebo-controlled phase 3 study (SUMMIT) including 731 adults with obesity (364 randomized to tirzepatide treatment). The dual primary endpoints were the composite of adjudication-confirmed cardiovascular death or heart failure events, analyzed as time to first event, and the change from baseline to week 52 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS). Patients were treated with the MTD up to 15 mg of tirzepatide or placebo, once weekly, and followed for a median duration of 104 weeks.

Patients had a mean age of 65.2 years, 21.0 % were 75 years of age or older, and 53.8 % were women. At randomization, 72.5 % of patients were classified as NYHA Class II, 27.5 % as Class III/IV, and 48.2 % had type 2 diabetes mellitus. Mean BMI at baseline was 38.2 kg/m<sup>2</sup>, and median eGFR was 62.0 ml/min/1.73 m<sup>2</sup>. Baseline heart failure therapy included renin-angiotensin-system inhibitors (80.4 %), diuretics (73.6 %), beta blockers (69.5 %), mineralocorticoid receptor antagonists (35.0 %), and 17.2 % used SGLT2i.

Tirzepatide demonstrated superiority compared with placebo in reducing the risk of worsening heart failure assessed as the composite of cardiovascular death or heart failure event, defined as heart failure hospitalization, urgent heart failure visits, or oral diuretic intensification for worsening heart failure (see Figure 13 and Table 15). Tirzepatide treatment also resulted in a statistically significant improvement in heart failure symptoms and physical limitations compared with placebo, as assessed by KCCQ-CSS (Table 15).



# Participants at Risk		364	359	349	344	340	338	333	284	275	251	228	220	196	167	146	105	82	46
MOUNJARO MTD		364	359	349	344	340	338	333	284	275	251	228	220	196	167	146	105	82	46
Placebo		367	361	349	339	332	328	318	268	259	240	219	215	195	165	145	94	73	45
Cumulative # Participants with Events		0	5	11	18	18	20	24	26	29	29	30	33	34	36	36	36	36	36
MOUNJARO MTD		0	5	11	18	18	20	24	26	29	29	30	33	34	36	36	36	36	36
Placebo		0	5	11	18	23	27	35	42	43	45	47	48	48	50	53	55	56	56

**Figure 13: Time-to-first event analysis for the composite of adjudication-confirmed cardiovascular death or heart failure events over a median follow up of 104 weeks**

**Table 15. SUMMIT: Dual primary endpoint results**

	<b>Tirzepatide MTD</b>	<b>Placebo</b>
<b>N</b>	364	367
<b>Composite of adjudication-confirmed cardiovascular death or heart failure events<sup>a</sup> over a median follow up of 104 weeks, n (%)</b>	36 (9.9)	56 (15.3)
Hazard ratio vs placebo (95% CI)	0.62* (0.41, 0.95)	-
<b>Cardiovascular death, n (%)</b>	10 (2.7)	5 (1.4)
Hazard ratio vs placebo (95% CI)	1.99 (0.68, 5.81)	-
<b>Heart failure events<sup>a</sup>, n (%)</b>	29 (8.0)	52 (14.2)
Hazard ratio vs placebo (95% CI)	0.54 (0.34, 0.85)	-
<b>Hospitalization for heart failure, n (%)</b>	12 (3.3)	26 (7.1)
Hazard ratio vs placebo (95% CI)	0.44 (0.22, 0.87)	-
<b>Urgent visit for heart failure, n (%)</b>	5 (1.4)	12 (3.3)
Hazard ratio vs placebo (95% CI)	0.41 (0.14, 1.16)	-
<b>ODI for worsening heart failure, n (%)</b>	17 (4.7)	21 (5.7)
Hazard ratio vs placebo (95% CI)	0.80 (0.42, 1.52)	-
<b>KCCQ-CSS (points) at week 52<sup>b</sup></b>		
Baseline mean	54.2	53.0
LS mean change from baseline	24.8	15.0
Difference from Placebo [95% CI]	9.8** [7.1, 12.5]	-

\* p < 0.05 versus placebo, adjusted for multiplicity.

\*\* p < 0.001 versus placebo, adjusted for multiplicity.

<sup>a</sup> Heart failure events were defined as heart failure hospitalization, urgent visit for heart failure or oral diuretic intensification (ODI) for worsening heart failure. Based on time-to-first event analysis for all randomized patients regardless of adherence to the study drug; a patient may

be counted in multiple components.

<sup>b</sup>Analysis based on the on-treatment data, excluding data after study treatment discontinuation.

Treatment with tirzepatide also reduced body weight and high sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation. Treatment with tirzepatide also significantly improved exercise capacity compared with placebo, as assessed by 6-minute walk distance (6MWD).

#### Blood pressure

In a placebo-controlled HFpEF phase 3 study, treatment with tirzepatide resulted in a mean decrease in systolic and diastolic blood pressure of 4 mmHg and 1 mmHg, respectively. Mean changes in systolic and diastolic blood pressure were <1 mmHg in placebo-treated patients.

#### Plasma and total blood volumes

In patients with HFpEF and obesity, tirzepatide reduced estimated plasma and total blood volume.

#### Cardiac function and structure

In a cardiac magnetic resonance imaging sub-study of SUMMIT, tirzepatide demonstrated a statistically significantly greater reduction in left ventricular mass compared to placebo, with a least square (LS) mean change difference of -11.18 g. Additionally, a statistically significantly greater reduction in paracardiac fat volume (the sum of epicardial and pericardial fat) was observed, which was driven by the reduction of pericardial fat.

#### Special populations

The efficacy of tirzepatide for the treatment of type 2 diabetes was not impacted by age, gender, race, ethnicity, region, or by baseline BMI, HbA1c, diabetes duration and level of renal function impairment.

The efficacy of tirzepatide for weight management was not impacted by age, gender, race, ethnicity, region, baseline BMI, or presence or absence of prediabetes.

The efficacy of tirzepatide for the treatment of moderate to severe OSA in patients with obesity was not impacted by age, sex, ethnicity, baseline BMI, or baseline OSA severity.

The efficacy of tirzepatide for HFpEF was not impacted by age, gender, race, ethnicity, region, baseline BMI, NYHA class, NT-proBNP levels, renal function, use of SGLT2i, or the presence or absence of type 2 diabetes mellitus.

#### Paediatric population

The licensing authority has deferred the obligation to submit the results of studies with Mounjaro in one or more subsets of the paediatric population for the treatment of type 2 diabetes mellitus and for weight management (see section 4.2, 4.8 and 5.1 for information on paediatric use).

## **5.2 Pharmacokinetic properties**

Tirzepatide is an amino acid sequence with a C20 fatty diacid moiety that enables albumin binding and prolongs half-life.

### Absorption

Maximum concentration of tirzepatide is reached 8 to 72 hours post dose. Steady state exposure is achieved following 4 weeks of once weekly administration. Tirzepatide exposure increases in a dose proportional manner.

Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.

Absolute bioavailability of subcutaneous tirzepatide was 80 %.

### Distribution

The mean apparent steady-state volume of distribution of tirzepatide following subcutaneous administration in patients with type 2 diabetes is approximately 10.3 L, and 9.7 L in patients who are overweight or have obesity.

Tirzepatide is highly bound to plasma albumin (99 %).

### Biotransformation

Tirzepatide is metabolised by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety and amide hydrolysis.

### Elimination

The apparent population mean clearance of tirzepatide is approximately 0.06 L/h with an elimination half-life of approximately 5 days, enabling once weekly administration.

Tirzepatide is eliminated by metabolism. The primary excretion routes of tirzepatide metabolites are via urine and faeces. Intact tirzepatide is not observed in urine or faeces.

### Special populations

#### *Age, gender, race, ethnicity, body weight*

Age, gender, race, ethnicity or body weight, do not have a clinically relevant effect on the pharmacokinetics (PK) of tirzepatide.

#### *Renal impairment*

Renal impairment does not impact the PK of tirzepatide. The PK of tirzepatide after a single 5 mg dose was evaluated in patients with different degrees of renal impairment (mild, moderate, severe, ESRD) compared with subjects with normal renal function and no clinically relevant differences were observed. This was also shown for patients with both type 2 diabetes mellitus and renal impairment based on data from clinical studies.

#### *Hepatic impairment*

Hepatic impairment does not impact the PK of tirzepatide. The PK of tirzepatide after a single 5 mg dose was evaluated in patients with different degrees of hepatic impairment (mild,

moderate, severe) compared with subjects with normal hepatic function and no clinically relevant differences were observed.

#### Paediatric population

The exposure in paediatric patients aged 10 to below 18 years with type 2 diabetes mellitus treated with tirzepatide 5 mg and 10 mg was comparable to that observed in the adult population.

### **5.3 Preclinical safety data**

Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology or repeat-dose toxicity or genotoxicity.

A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5 mg/kg (0.12, 0.36, and 1.02-fold the maximum recommended human dose (MRHD) based on AUC) administered by subcutaneous injection twice weekly. Tirzepatide caused an increase in thyroid C-cell tumours (adenomas and carcinomas) at all doses compared to controls. The human relevance of these findings is unknown.

In a 6-month carcinogenicity study in rasH2 transgenic mice, tirzepatide at doses of 1, 3, and 10 mg/kg administered by subcutaneous injection twice weekly did not produce increased incidences of thyroid C-cell hyperplasia or neoplasia at any dose.

Animal studies with tirzepatide did not indicate direct harmful effects with respect to fertility.

In juvenile rats, tirzepatide caused delayed sexual maturation in both males and females which was secondary to pharmacological effects on body weight. Findings did not suggest any specific risk for use in the paediatric population.

In animal reproduction studies, tirzepatide caused foetal growth reductions and foetal abnormalities at exposures below the MRHD based on AUC. An increased incidence of external, visceral, and skeletal malformations and visceral and skeletal developmental variations were observed in rats. Foetal growth reductions were observed in rats and rabbits. All developmental effects occurred at maternally toxic doses.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium phosphate dibasic heptahydrate  
Sodium chloride  
Concentrated hydrochloric acid, and sodium hydroxide (for pH adjustment)  
Glycerol  
Phenol  
Benzyl Alcohol  
Water for injections

## **6.2 Incompatibilities**

In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products.

## **6.3 Shelf life**

*Before use*

24 months

*After first use*

For storage conditions after first use of the medicinal product, see section 6.4.

## **6.4 Special precautions for storage**

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

After first use, Mounjaro may be stored unrefrigerated for up to 30 days at a temperature not above 30 °C and then the pre-filled KwikPen must be discarded.

## **6.5 Nature and contents of container**

Each pre-filled KwikPen contains 30 mg of tirzepatide in 2.4 ml solution.

Pack sizes of 1 and 3 pre-filled KwikPens. Not all pack sizes may be marketed.

Needles are not included in the pack.

## **6.6 Special precautions for disposal**

### Instructions for use

Inspect Mounjaro visually before use and discard for particulate matter or discolouration.

Mounjaro that has been frozen must not be used.

The pre-filled KwikPen is for multiple-doses. Each KwikPen contains 4 doses of 0.6 ml which can be administered. Any excess solution in the pen after use should be discarded.

The instructions for using the pre-filled KwikPen, and the package leaflet, must be followed carefully.

### Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7      MARKETING AUTHORISATION HOLDER**

Eli Lilly Nederland B.V., Orteliuslaan 1000, 3528 BD Utrecht, The Netherlands

**8      MARKETING AUTHORISATION NUMBER(S)**

PLGB 14895/0342

**9      DATE OF FIRST AUTHORISATION/RENEWAL OF THE  
AUTHORISATION**

25/01/2024

**10     DATE OF REVISION OF THE TEXT**

09/04/2026